Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1978

Regional Differences in Central Adrenergic Neuronal Activity
During Anesthesia
Byron C. Bloor
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Bloor, Byron C., "Regional Differences in Central Adrenergic Neuronal Activity During Anesthesia" (1978).
Dissertations. 1780.
https://ecommons.luc.edu/luc_diss/1780

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1978 Byron C. Bloor

REGIONAL DIFFERENCES IN CENTRAL
ADRENERGIC NEURONAL ACTIVITY DURING ANESTHESIA

by
Byron C. Bloor

A Dissertation Submitted to the Faculty of the Graduate School
of Loyola University of Chicago in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy

DECEMBER
1978

ACKNOWLEDGMENTS

My sincerest thanks to every member of my
dissertation committee for their in valuable contributions made toward this manuscript.
A very special thanks must be given to
Dr. S.N. Glisson, my advisor throughout my Ph.D.
training, for his endless patience, creativity
and supervision.

ii

VITA

The author, Byron C. Bloor, is the son of
Byron M. Bloor and Noreen (Conway) Bloor.

He was

born April 16, 1951 in Durham, North Carolina.

His secondary education was obtained at Morgantown
High School.

In September, 1969 he entered West Virginia

University where he majored in biology until transfering
to Loyola University of Chicago in February of 1971.
In June of 1973 Mr. Bloor received a Bachelor of Science
degree in Psychology.

In September of 1973, Mr. Bloor was accepted as
a graduate student by the Department of Pharmacology and
Experimental Therapeutics Loyola University, Stritch School
of Medicine.

While a graduate student he was awarded a

National Institutes of Health Traineeship and named a
Basic Science Fellow.

He is Currently a member of Sigma

Xi, the American Association for the Advancement of Science
and the American Chemical Society.

iii

TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS
VITA

ii

• • • • •

LIST OF TABLES

iii

............

.........

LIST OF ILLUSTRATIONS

vi
vii

CONTENTS OF APPENDICES

• • vi i i

Chapter
I.

INTRODUCTION AND REVIEW OF LITERATURE •
Biophysical Anesthetic Mechanism
Lipid Theory • • • • • • • • • •
Fluidized Lipid Hypothesis
Phase Transition Hypothesis ••
Lateral Phase Separation
••••••
Protein Related Biophysical Anesthetic
Mechanism Theories • • • • • • • • • • • •
Surface Tension Theory . • • • • • •
Colloid Theories • • • • . • • • • .
Protein Conformational Change Theory
Other Proposed Biophysical Mechanisms of
Anesthetic Action • • • • • . • • . • • . •
Macromolecular Site of Anesthetic Action
Adrenergic Neuropathways • •
• • • • . •
Dopami nergi c Pathways • •
• •
Noradrenergic Pathways • • • • •
Ketami ne • • • • • • • • • • • •
. • •
Halothane
• • •
. • •
Nitrous Oxide
. •

II.

1

1
3

4
5
6
8
8
9

11

• •

15
16
• • • • 18
• • . • 20
• ••• 23
• •
29
• •
38
• .
45

METHODS
Animals • . • . • • • . •
Basic Turnover Techniques
Specific Methodologies •.
Tissue Samples ••••
Catecholamine Extraction
Column Preparation • • • . •
Catecholamine Ion Exchange Column
Chromatograph •
• • . . • •
i v

51
53
64
64

65
66
68

TABLE OF CONTENTS (CONT.)

Page
Catecholamine Quantification • • • • • • • •
Calculation of the Isotopic Catecholamine
Run Off Slope • • • • • • • • • • • • • • •
Computer Calculation of Data • • • • • • • • • •
Volatile and Gaseous Anesthetic Delivery
System for Halothane and Nitrous Oxide
Drug Scheduling
••••
Ketami ne • • • • • • • • • • • • • • •
Halothane • • • • • • • • • • •
Nitrous Oxide • • • • • • • • • •
Halothane Plus Nitrous Oxide
I I I.

0

•••

0

• • • • • • •

0

0

o

0

o

••••

•••

••••••••••

Cortex . . . . . . . . . . . . . . . . . . .

Turnover and Endogenous Levels as Compared
to Awake Control • • • • • • • • • •
Comparison of Turnover and Endogenous
Levels Between Anesthetics
• ·• •

SUMMARY •

81
83
85
91
91
94

97
98

RESULTS
Introduction ••
Mesencephalon • • • • • •
• •
Turnover and Endogenous Level as Compared
to Awake Control
•
Comparison of Turnover and Endogenous
Levels Between Anesthetics
Thalamus •••••
Turnover and Endogenous Levels as Compared
to Awake Control • • • • • • • • • •
Comparison of Turnover and Endogenous
Levels Between Anesthetics
Hypotha 1amus • • • • • • • • • • • • • • •
Turnover and Endogenous Levels as Compared
to Awake Control • • • • • • • • • • •
Comparison of Turnover and Endogenous
Levels Between Anesthetics

IV.

70

DISCUSSION .

..........
........

REFERENCES

100
102
102
112

116
116
126
130
130
130
140
144
144
154
163
179
181

v

LIST OF FIGURES

Number

Title

Page

1

Catecholamine Metabolic Scheme . ... ..... ...

54

2

Typical Run Off Slope .... .... .. .. .........

60

3

Anesthetic Circuit........................

87

4

Mesencephalon: Endogenous Levels as
Percent of Awake Control .. . ... .. .... .. .. ..

105

Mesencephalon: Turnover as Percent
of Awake Control . . . . . . . . . . . . . . . . . . . . . . . . . .

110

Thalamus: Turnover as Percent of
Awake Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

119

Thalamus: Endogenous Levels as
Percent of Awake Control ... . .. .. .. ...... ..

124

Hypothalamus: Turnover as Percent
of Awake Control . . . . . . . . . . . . . . . . . . . . . . . . . .

133

Hypothalamus: Endogenous Levels as
Percent of Awake Control .... ...... .. .. ....

138

10

Cortex: Turnover as Percent of
Awake Control . • . . . . . . . . . . . . . . . . . . . . . . . . . . .

147

11

Cortex: Endogenous Levels as
Percent of Awake Control ... ..... ... .. .. ...

152

Halothane Recovery: Turnover as
Percent of Awake Control . ...... ...........

158

Halothane Recovery: Endogenous Levels
as Percent of Awake Control ....•..........

161

5
6

7
8
9

12
13

vi

LIST OF TABLES

Number

Title

Page

1

Fluorometric Conversion of Norepinephrine .

71

2

Calculation of Endogenous NE and DA

74

3

Fluorometric Conversion of Dopamine

78

4

Calculation of the Isotopic Catecholamine
Run 0 ff S1 ope ............................ .

82

5

Mesencephalic Dopamine Data .............. .

10 3

6

Mesencephalic Norepinephrine Data ..•......

107

7

Mesencephalic Anesthetic Cross Comparisons

114

8

Thalamic Dopamine Data ................... .

117

9

Thalamic Norepinephrine Data ............. .

121

10

Thalamic Anesthetic Cross Comparisons .....

128

11

Hypothalamic Dopamine Data ............... .

131

12

Hypothalamic Norepinephrine Data ......... .

135

13

Hypothalamic Anesthetic Cross Comparisons .

142

14

Cortical Dopamine Data ................... .

145

15

Cortical Norepinephrine Data ............. .

150

16

Cortical Anesthetic Cross Comparison ..... .

156

vii

CONTENTS FOR APPENDICES
Page
Appendix A: Brain Weights ..•.•.........•.•.......

200

Appendix B: Monitoring Values .....•..............

201

vi i i

ABB RE VI AT I 0 NS
a

alpha

AMPT

alpha-methyl-para-tyrosine

14c

carbon 14 label isotope

C

centigrade

em

centimeter

co 2

carbon dioxide

CPM

counts per minute

DA

dopamine

DPM

disintegrations per minute

DPS

dorsal periventricular system

DTB

dorsal tegmental bundle

EDTA

ethylenedinitrilo-tetraacetic acid

EEG

electroencephalography

g

gravitational force

G

grams

GABA

gamma-amino butyric acid

GHB

gamma-hydroxybutyrate

3H

tritium

HCl

hydrochloric acid

5-HT

serotonin

HVA

homovanilic acid

kg

kilogram

M

molar

MAC

minimun alveolar concentration
ix

A B B R E V I A T I 0 N S (cont.)
MFB

medial forebrain bundle

mg

milligram

min

minute

ml

milliliter

mm

millimeter

N

normal

NE

norepinephrine

ng

nanogram

nM

nanometer

N20

nitrous oxide

02

oxygen

p

probability

PCPA

parachlorophenylalanine

SE

standard error of the mean

torr

millimeter mercury

uMHg

micrometer mercury

VPS

ventral periventricular system

X

CHAPTER I
INTRODUCTION AND REVIEW OF LITERATURE
Biophysical Anesthetic Mechanism
The study of the mechanism of anesthetic action
has been approached by a surprisingly diverse group of
disciplines.

These studies have arisen from almost every

type of laboratory in the biological and chemical sciences.
The resulting milieu is clouded and filled with many
diverse theories.

With this in mind, I have taken the

liberty to group these theories into two subgroups, the
protein theories and the lipid theories, in an attempt to
gain semblance.

First, a few basic concepts should be

considered to help gain insight into these theories which
suggest a unitary molecular site of anesthetic action.
General anesthesia is produced by a wide variety
of compounds with no common chemical
activity.

structur~

or chemical

Some examples of the diverse chemical natures

of agents that produce general anesthesia would include
aliphatic, aromatic, halogenated hydrocarbons, alcohols,
aldehydes, ketones, esters, and ethers (Kaufman, 1977).
Even the nitrogen in the air we breathe has anesthetic
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properties (Paton, 1967; Winter, et al ., 1975).

Important-

ly, it has been suggested that a specific receptor does
not play a significant role in anesthetic mechanisms.
This has been proposed largely for two reasons.

First,

the molecular size differential between a small molecule
(e.g., N20) and a large molecule (e.g., a steroidal
anesthetic) makes the feasibility of such a relationship
unlikely.

Second, stereoisomerism is an important criterion

for receptor delineation:

stereoisomers of most anesthet-

ics are equipotent (Kendig, et al ., 1973).
For many years it has been known that hydrostatic
pressure can modify- an organism•s response to drugs
(Cattel, 1936).

In fact, anesthesia itself is generally

reversed with increased atmospheric pressure.

Johnson and

Flagler (1950) first made the observation that tadpoles
narcotized with a 2 - 5%

~thanol

would resume swimming in

an apparently normal manner following application of
pressure.

Similar hyperbaric reversal of anesthesia has

been demonstrated for ether, halothane, barbiturates, and
nitrous oxide.

Even though much work remains to be done

in this field, pressure reversibility of anesthesia is an
important aspect in the consideration of anesthetic
biophysical models.

--3

Lipid Theory
The first and certainly the most successful
biophysical theory of anesthetic mechanisms arose from the
observations of Meyer (1899) and Overton (1901).

This

theory, the lipid solubility theory of anesthetics, was
best stated in Meyer's 1937 paper:

"Narcosis commences

when any chemically indifferent substance has attained a
certain molar concentration in the lipids of the cell.
This concentration depends on the nature of the animal or
cell, but is independent of the narcotic."
In 1954, Mullins reformulated the lipid theory of
anesthesia resulting in the critical volume theory which,
even today, acts as a basis for lipid theories of anesthesia.

The critical volume hypothesis is based on a

simple model of solvents.

It accounts accurately for both

the relative potencies of gaseous anesthetics and for
pressure reversal of anesthesia.

Simply stated the theory

proposes that anesthesia commences when a certain critical
volume fraction of an inert substance is attained in
membranes.

The critical volume of an anesthetic entering

the membrane can be thought of as that volume which fills
up the free volume of the membrane.

The resulting compres-

sion caused by a volume increase in the membrane lipid
bilayer influences the membrane proteins essential to

4

neural function.

Mull ins believed the resultant protein

modification would effect sodium or potassium channels,
neurotransmitter receptor conformation, or enzyme systems
that affect neurotransmitters.

Highly specific supportive

evidence to affirm this theory comes from the theory's
capability to predict both the excitation of the nervous
system at high pressure (high pressure neurological
syndrome; Miller, 1974) and the pressure reversibility of
anesthesia.

Three subsequent interpretations of the

critical volume theory have recently surfaced:

(a) the

fluidized lipid hypothesis, (b) the phase transition
hypothesis and (c) the lateral phase separation hypothesis.

(a) Fluidized Lipid Hypothesis:
The original critical volume hypothesis proposed by Mullins suggested that the anesthetic filled
up the

11

free volume 11 in the membrane in such a way as

not to allow for protein accommodation necessary for
nerve function.

Work by Hubbell et al. (1970), and

Seeman (1975) has not supported this "free volume ..
concept.

Instead, the critical volume of anesthetic

entering the membrane was thought to expand the membrane.

The resulting disorder caused by the volume

increase in the membrane lipid bilayer would result

5

in decreased membrane viscosity.

Although this theory

modification does not address itself directly to the
problem of how a fluidized membrane might interfere with
nerve performance, and therefore anesthesia, it does
correct the critical volume theory in the light of the
new data.

Gage and Hamill (1976) attempted to link the fluidized

membrane with its physiological performance.

He suggested

a decrease in membrane viscosity as affecting the function
of the membrane ionophores and thus membrane polarization.

(b) Phase Transition Hypothesis:
The phase transition hypothesis of Lee (1976) has
an advantage over the fluidized lipid hypothesis in that
it provides a direct mechanism by which the anesthetic
agents effect nerve function.

He postulates an annulus

lipid structure in the gel state gating the sodium channel.
The excitable protein is

11

COntrolled" by this lipid annulus

and thus this lipid hypothesis has a direct link between
lipid and protein mechanisms.

Specifically, this theory

states that "an anesthetic agent •melts• (phase transition)
the lipid annulus stabilizing the channel in its closed
state. 11

(c) Lateral Phase Separation:
The last of the three modifications dealing with

p
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the critical volume theory was originally proposed by
Shimshick and McConnel

(1973), however Trudell (1977)

later incorporated Shimshick's theory into a unitary
theory of anesthesia based on lateral phase separation.
As defined by Shimshick, "lateral phase separation occurs
in phospholipid bilayer membranes when highly ordered gel
phase phospholipids and disordered fluid-phase phospholipids coexist."

The borders between solid and fluid-phase

in a phospholipid bilayer are called lateral phase separations.

Accordingly, the phospholipid bilayer is able to

accommodate volume change by transforming high volume
disordered chains to lower-volume ordered chains (Shimshick
and McConnell, 1973).
bility.

This is termed lateral compressi-

As stated previously, proteins have been shown to

change conformation during normal function (Low and
Somera, 1975) and during anesthesia (Seeman, 1972).

This

evidence suggests that lateral compressibility is necessary
for some cellular processes.

Steer and Levitzki (1973) and

Bretscher and Raff (1975) have in fact described phase
transition in lipid surrounding enzyme systems and membrane
proteins in mammals.

The lateral phase theory goes on to

suggest that application of an anesthetic agent to the
membrane bilayer results in a disordered configuration of
fatty-acid chains near the protein with no lateral

7
compressibility.

Once disordered by the anesthetic agent

the protein would require a large amount of energy in order
to expand or change configuration.

In effect, the lipid

is not able to assume its lower volume solid phase necessary
for protein rearrangement.

When a sufficient number of

nerve membrane protein molecules are functionally blocked
the cell or organism is then anesthetized.
Various models dealing with protein conformation
changes necessary for nerve function are discussed in the
section on protein theories of anesthesia.

It is important

to note at this time that each of the protein theories to
be discussed in that section could be adequately explained
in terms of lateral compressibility.

One theory unrelated

to a protein mechanism was proposed by Taupin and McConnel
(1975) and later by Van der Bosch and McConnel (1975)
suggesting that lateral phase separation blocks exocitosis
without protein involvement.

•
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Protein Related Biophysical Anesthetic Mechanism Theories
The rationale of an anesthetic-protein interaction
in the past has been questioned.

This was due to the well

known fact that anesthetics are highly lipid soluble
(hydrophilic) while protein molecules are generally polar
(hydrophobic) making protein an unlikely locus for anesthetic action.

With current knowledge of protein structure

many amino acid residues have been considered to be
hydrophobic when in peptide side chains.

These amino acids

are glycine, alanine. valine, leucine, isoleucine, proline,
phenylalanine, and methionine.

If anesthetic agents do

work directly upon protein it would be these lipid soluble
amino acids of the side chains that interact with the
anesthetic agents.
Further support for a direct anesthetic-protein
interaction came from Balasubramanian and Wetlaufer (1966).
They confirmed that gaseous anesthetics interact with
protein and changed the conformation of the protein side
chains without affecting the basic a-helical configuration
of the peptide chains.

Schoenborn (1968) and Schoenborn

et al. (1965) have further delineated these sites.

For

historical continuity, each theory will be discussed.

a) Surface Tension Theory:
The first of the protein theories began possibly

•
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with Traube (1904) and Lillie (1909).

They observed that

anesthetic potency could be related to the ability to lower
surface tension.

To elucidate the mechanism Clements and

Wilson (1962) reformulated earlier theories of Lillie
(1909) and Warburg (1921) describing the interaction
of general anesthetics with surface films of protein.

An

alteration of the surface protein was proposed to cause a
change in neural transmission and thus cause anesthesia.
The surface tension theory is, historically, the origin
of the current day protein conformational change theory
to be discussed later.

b) Colloid Theories:
A second protein theory had its origin in the late
eighteenth century.

Proposed by Claude Bernard in 1875,

and formalized by Bancroft and Richter in 1931, the
colloid theory suggested reversible aggregation of all
colloids causing anesthesia.

Reversible cessation of

protoplasmic streaming has been demonstrated in slime mold
following the addition of chloroform, cyclopropane and
ethylchloride (Seifritz, 1950).

Heilbrunn (1952) observed

that viscosity of the cytoplasm of slime molds and algae
was decreased by low anesthetic concentrations and
increased by high concentrations.

Bruce and Christiansen

p
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(1966) showed that diethyl ether and halothane inhibited
protoplasmic streaming in the amoeba.
The colloid theory culminated in the current
day microtubule theory.

Proposed in 1968 by Allison and

Nunn, microtubule inhibition was suggested as the underlying mechanism by which the anesthetic agent produced
viscosity changes and anesthesia.

Subsequently, Allison

et al. (1970) demonstrated that five inhalation anesthetics
produce reversible dispersion of microtubules in heliozoa
at concentrations of 2 to 4 MAC (minimum alveolar concentration) and nitrous oxide at concentrations below 1 MAC.
The relevance of these findings to the understanding of anesthesia is questionable.

Other investigators

have failed to show an effect of pentobarbital and
halothane on microtubules in mouse optic nerve (Sauberman
and Gallagher, 1973).
squid axons

It was also demonstrated that

continued to

conduct action

potentials

following removal of 95% of the axoplasm which suggests
that microtubules are not necessary for axonal conduction.
Colchicine, podophyllotoxin, vinblastine, and griseofulvin
each have the ability to disrupt the microtubule system.
Katz (1972) found that colchicine and podophyllotoxin
decrease transmitter release from frog neuromuscular
junction, however, as these drugs were shown to act on
nerve terminal membranes, he concluded that the effects on

11

transmitter release were independent of microtubular
effects.

Further, colchicine and vinblastine inhibited

acetycholine-induced catecholamine release from the
perfused bovine adrenal gland and blocked transmission
through the superior cervical ganglia of the cat (Trifaro
et al ., 1972), actions which were attributed to the
anti-cholinergic effects of these drugs and not to
microtubular actions.

Further problems shrouding this

theory include its inability to account for pressure
reversibility of anesthesia (Salmon, 1975) and the ability
of anesthetics to release calcium with only incidental
effects on microtubules.

Supporters will, however, cite

variability of microtubules within individual cells
(Behnke and Forer, 1967) and between cell types and
species as the cause of the discrepancies (Olmsted et al .,
1971).

As a result of the conflicting data and a general

lack of investigative support, the microtubule theory of
anesthetic action has not been well accepted.

c) Protein Conformational Change Theory:
The most favorable protein related anesthetic
mechanism theory revolves around protein conformational
changes as a result of anesthesia.

This theory stems from

both the surface tension theory (previously discussed) and
from a bacterial enzyme model.

.....
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Photobacterium phosphoreum possess a light producing system which is sensitive to anesthesia.

This light

production results from the interaction of the enzyme
luciferase with

reduced flavin mononucleotide and oxygen.

The light emission is proportional to the reaction velocity
(Johnson and Eyring, 1948).

It has been shown that a wide

variety of anesthetic agents, including halothane,
chloroform, cyclopropane, and ether at equipotent clinical
anesthetic doses produces an inhibition of luminescence of
this type which is reversible by application of hyperbaric
pressure (Johnson et al ., 1942; White and Dundas, 1970;
Halsey and Smith, 1970).

The anesthetic produced inhibi-

tion of luminescence is believed to be due to a conformational change of the luciferase enzyme.
Seeman (1972) and Low and Somero (1975), who have
demonstrated membrane expansion associated with anesthesia,
found that the increase in membrane volume was about 10
times the occupying volume of the anesthetic in the membrane protein suggesting conformational changes in the
membrane protein.

Eyring (1973) suggested this conforma-

tional change resulted from membrane unfolding such that
the membrane occupied a larger volume.

In this connection,

Eyring (1973) has described the effect of anesthetics on
protein conformational change in terms of a thermodynamic
change.

Hill (1974) proposed a thermodynamic description

p
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of general anesthesia in terms of the "Gibbs" free energy
\.

of the anesthetic site.

The advantage of Hill's theory

is that the outcome of the interaction can be predicted
without knowledge of the mechanistic details of that
process.
Thermodynamic analysis of firefly luminescence
has been applied by Ueda and Kamaya (1973) to the anesthetic action of methoxyflurane, chloroform, halothane,
enflurane and fluroxene suggesting their site of action
at a hydrophobic site on luciferase inducing a structural
membrane

11

Unfolding ...

There are many ways by which protein conformational
change may affect neural function.

Protein conformational

change or "unfolding" may (a) prevent the association of
protein into ion channels, (b) depress the transmitter
release by preventing vesicular and presynaptic membrane
fusion, (c) inhibit rate limiting enzymes, or (d) affect
the postsynaptic membrane receptor.

Any or all of these

effects may be involved.
Although not as well supported as the lipoid
anesthetic model, the protein-based anesthetic interaction
model is certainly viable.

It is also clear that no

single theory will explain the effects of all anesthetic
agents.

A hydrophobic protein site of action can explain

many of the physiochemical relationships cited.

•
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An important common denominator between all
theories developed that must be stressed is that, at best,
all of these theories are descriptive in nature.

They

describe the effect of anesthetics rather than a mechanism
by which these effects are produced.

p
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Other Proposed Biophysical Mechanisms of Anesthetic Action
Two seemingly important models for anesthetic
action were proposed independently by Miller (1961) and
Pauling (1961) and were popularized in the past decade.
These theories fit neither the protein nor the lipid
theories of anesthesia.

Pauling and Miller each suggested

that the site of action of anesthetics lies in the aqueous
water phase of the nerve cell.

Both investigators

established a relationship between anesthetic potency and
highly ordered water molecules orientated around aqueous
solutions of gases (i.e., hydrated crystals).

Pauling

(1961) suggested the formation of mixed hydrates of
solutes in brain fluid and charged side-chains of protein
which are capable of forming stable hydrate substructures.
These hydrated microcrystals, or

11

Clathrates,

11

once

formed, were to result in increased neural impedance,
ionophore blockage, or altered enzymatic activity.

Both

theories have died from lack of evidence that clathrates
form at normal body temperatures.

p
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Macromolecular Site of Anesthetic Action
The theories of anesthesia developed thus far have
proposed or alluded to a specific biomolecular locus of
anesthetic action.

However, it becomes apparent from a

review of the literature that-sufficient evidence exists.
to imply that anesthetics have their primary neuronal action in the synaptic region at the macromolecular level
(Alper and Flacke, 1969; Brooks and Eccles, 1947; de Jong
et al ., 1968a; de Jong and Nace, 1967; DeRobertis, 1971;
Halsey and Smith, 1970; Ho and Keats, 1969; Karis et al .,
1966, 1967; Larrabee and Pasternak, 1952; Paton and
Speden, 1965; Richards, 1972, 1973).

Investigations into

anesthetic effects on synaptic elements have raised
several important questions:

Is the anesthetic action on

the synapse due to a direct lipid and/or protein interaction as suggested in the previously discussed theories?
Do anesthetics affect pre- or postsynaptic elements or
both?
It is widely believed that for a general anesthetic to have effect on a synapse it must directly or
indirectly cause the depression of nerve impulse conduction, depress presynap!ic transmitter release, result in
postsynaptic membrane conductance changes, or induce a
combination of these effects ultimately leading to a
depression of certain synapses in the central nervous

p
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system.

Balasubramanian and Wetlaufer (1966), Ho and

Keats (1969), Musick and Hubbard (1972) and others
consider these basic nerve functions to be performed by
membrane lipoproteins.

When considering the argument

between lipid or protein anesthetic interaction, Woodbury
et al. (1976) wittily

suggested

11

the parallelism between

the effects of anesthetics on lipids and proteins suggest
that research in these two fields are feeling different
parts of the same elephant. 11

As to which mechanism is

actually responsible for the anesthetic induced reduction
in synaptic transmission, it is too early to postulate.
There are many reputed central neurotransmitter
systems (i.e., cholinergic, adrenergic, gabaminergic,
and serotonergic).

Whether anesthetic agents affect all

transmitter system synapses uniformly or only select
transmitter systems in a discrete fashion has not been
determined.
This dissertation examines the effects of certain
anesthetic agents on the central adrenergic nervous
system.
follows.

A review of the known central adrenergic pathways

18

Adrenergic Neuropathways
Dopamine (DA) and norepinephrine (NE), each a
catecholamine, are considered to be putative neurotransmitters in the mammalian central nervous system.
Norepinephrine was first detected in the mammalian brain
by von Euler (1946).

Vogt (1954) later found that the

concentration of NE in brain was not evenly distributed
and did not parallel brain vasculature.

Von Euler further

demonstrated a close correlation between the content of
NE present and the proportion of nonmyelinated to myelinated nerve

fibers.

Further,

hypotha 1 ami c NE

concentration was found to be unaltered by cervical
sympathectomy.

These early findings led investigators to

propose a role for NE as a central neurotransmitter.
Dopamine, initially believed to be present in
mammalian brain solely as a precursor of NE (Carlsson,
1966), was found to be present in whole brain in concen-

trations higher than NE (Montagu, 1957; Weil-Malherbe
and Bone, 1957).

Later DA studies demonstrated a

distribution markedly different from that of NE (Cooper
et al., 1974).
Many studies have been subsequently performed to
establish the role of both NE and DA as central adrenergic
neurotransmitters.

Specific areas of catecholamine

research establishing their putative roles in the central

p
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nervous system have been extensively reviewed in the
literature.

(For reviews of specific areas cf.:

Biochemistry, Molinoff and Axelrod (1971 ); Function,
Hornykiewicz (1966), and Marley and Stephenson (1972);
Metabolism, Axelrod (1966 and 1971 ), Glowinski and
Baldessarini (1966), and Kopin (1972); Pharmacology,
Salmoiraghi et al. (1965), and Sulser and Sanders-Bush
(1971 ); Receptors, Curtis and Crawford (1969), and
Triggle (1972); Release, Glowinski (1970), andSmith et al.
(1977); Synthesis, Kopin (1968), Axelrod (1971), and
Costa and Meed (1974); Transport and Storage, Glowinski
(1970), and Shore (1972); Uptake, Iversen (1970 and
1971)).
Instrumental in outlining the central anatomical
pathways of the catecholaminergic neurons have been
fluorescence methodologies.

First developed by a Swedish

research group headed by Eranko (1955) and later improved
by Falck and Hillarp (Falck et al., 1962; Falck, 1962)
catecholamine neurons were shown to fluoresce when exposed
to vaporized formalin.

Lindvall and Bjorklund (1974) and

Lindvall et al. (1974) have recently introduced the use of
glyoxylic acid instead of formaldehyde to produce monamine
fluorescence of greater intensity.

Since the amount of

fluorescence produced is proportional to the amount of
catecholamine present, several techniques are usually
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employed to alter endogenous catecholamine levels and
·therefore change fluorescence visibility.

This includes

drugs such as reserpine and monoamine oxidase inhibitors,
lesioning to increase proximal axonal amine content
(Anden et al ., 1974; Ungerstedt, 1971 ), and cytotoxic
compounds for system delineation (Snyder et al ., 1970a;
Ungerstedt, 1968; Baumgarten et al ., 1971 ).
Recent developments have led to the introduction
of a highly sensitive and selective immunocytochemical
peroxidase-antiperoxidase system to identify and localize
enzymes necessary for catecholamine production.

A com-

parison of data from existing techniques leads to the
delineation of distinct dopaminergic and noradrenergic
pathways (cf. below).

Dopaminergic Pathways:
The majority of dopaminergic cell bodies lie in
mesencephalon and give rise to an estimated 500,000
terminals (Cooper et al., 1974).

Three primary dopaminer-

gic pathways have been proposed.

Each of the three

pathways has been established with a large variety of
techniques, including fluorescence histochemistry, biochemistry, stains of terminal degeneration, and electron
microscopy (for a more extensive review of the literature
on techniques specific for DA cf. Moore and Dominic,
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1971; Carpenter and Peter, 1972).
a) The Nigrostriatal System:
The first dopaminergic pathway to be discussed is
the nigrostriatal system (i.e., cell groups A8 and A9, of
Dahlstrom and Fuxe, 1964).

The substantia nigra is the

largest nuclear mass in the mesencephalon (Carpenter and Peter,
1972).

The cell bodies lie primarily in the zona compacta

of the substantia nigra and project through the medial
forebrain bundle to the striate and amygdaloid nuclei.
Specific fibers in the caudal two-thirds of the nigra
project to portions of the putamen, while rostral parts
of the nigra project to the caudate nucleus.
It has been suggested that this nigro-neostriatal
dopaminergic system is related to the extrapyramidal motor
system.

As to whether this is its sole action is yet to

be determined.

Neurophysiologic data in support of this

pathway has shown that iontophoretically applied DA
to neurons of the cat caudate nucleus causes depression of
spontaneous neuronal firing (Connor, 1972).

An identical

response was elicited by electrical stimulation of the
substantia nigra.

Both nigral stimulation and iontophore-

tic DA application were shown to be blocked by a-methyldopamine.

It has been suggested that DA has an inhibitory

action at the caudate nucleus when released from cells
originating in the substantia nigra.

In contrast, York
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foJnd iontophoretically applied DA caused a facilitation
of neuronal firing in the cat putamen.

Electrical stimu-

lation of the substantia nigra elicited a similar
facilitation thus both facilitatory and inhibitory actions
of DA have been demonstrated (York, 1970).
b) The Mesolimbic System:
The second of the thrie DA pathways to be discussed
is the mesolimbic dopaminergic pathway.

The cell bodies

for these nerves arise in the medial mesencephalon just
dorsal to the interpeduncular nucleus (cell group AlO,
Dahlstrom and Fuxe, 1964); these fibers ascend medially to
the crus cerebri into the medial forebrain bundle
innervating the tuberculum offactorium and the nucleus
accumbens.

These nerve bundles run lateral to noradrener-

gic nerve tracts innervating the neostriatum.

The

function of the mesolimbic dopamine system is at present
unknown.
c) The Tuberoinfundibular System:
The cell bodies of the third known dopaminergic
system lie primarily in the arcuate nucleus of the
hypothalamus (Dahlstrom and Fuxe, 1964, cell groups #All12).

They innervate the external layer of the medial

eminence.

The dopaminergic neurons in this last system

behave differently from those found in the nigrostriatal
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or mesolimbic system.

The tuberoinfundibular system is

insensitive to the normal destructive action of 6hydroxydopamine and when activated for any length of time
becomes markedly depleted of transmitter stores.

It has

been suggested that the neurons in the system behave in a
manner similar to that of neurosecretory neurons.

Noradrenergic Pathways:
Noradrenergic cells give rise to large collateral
networks of fibers innervating many brain areas.

As an

example of this system's diffuse nature it has been shown
that in the case of the locus coeruleus one noradrenergic
cell body sends tracts to both the cerebral cortex and
the cerebellum.

The central noradrenergic system has both

ascending and descending tracts, most of which originate
in the pons and medulla oblongata.

Noradrenergic fibers

have been shown to innervate the thalamus, the preoptic
area, the amygdaloid nucleus, the hippocampus, cingulate
gyrus, the pyriform cortex, the striatal terminalis, the
septal areas, the neocortex, and several hypothalamic
nuclei.

The ascending noradrenergic system has its cells

of origin in the medulla and pons, Dahlstrom and Fuxe
(1964), areas A-1, A-2, A-5, A-6, and A7.
Due to the diffuse projections of the noradrenergic
systems it is easier to construct a general picture of this
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system by considering the four major noradrenergic conduction pathways:

(a) the central tegmental tract, (b) dorsal

tegmental bundle, (c) the periventricular fiber system,
and (d) the medial forebrain bundle.
will follow for each.

A brief description

A more complete description is

included in the works of Dahlstrom and Fuxe (1964),
Ungerstedt (1971 ), and Lindvall and Bjorklund (1974).
(a) The central tegmental tract (CTT)
The central tegmental tract is usually considered
to be a highly heterogeneous system of longitudinally
running fibers in the reticular

fo~mation.

The ascending

system is comprised of cells originating in three locations:

(1) spinal cord, (2) the medullary reticular

formation (groups Al and A2), and (3) the pons (from cell
group AS situated lateral to the superior olivary nucleus,
A7, the subcoeruleus, and A6, the locus coeruleus).
Lindvall and Bjorklund (1974)

also

reported vertical

T-shaped noradrenergic fibers in this pathway interconnecting the CTT with the periventricular grey.
(1974) and Lindvall and Bjorklund (1974)

Chu and Bloom

have

suggested

that these vertically arranged fiber systems represent
collateral branches from the CTT to give rise to an
extensive terminal system distributed in the locus
coeruleus, dorsal raphe nucleus, and the periventricular
grey system.
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(b) Dorsal tegmental bundle (DTB)
The dorsal tegmental bundle is an ascending
homogeneous group of noradrenergic fibers arising from
the locus coeruleus (A6).

Soon after the DTB emerges

from the locus coeruleus, the crossing fibers deviate
medially from the DTB.

Along its course the tract ascends

lateral to the medial longitudinal fasciculus.

While still

in the mesencephalon, the DTB gives off fibers just
rostral to the decussation of the superior cerebellar
peduncles (i.e., at the level of the inferior colliculus)
to the tegmental radiation.

At the meso-diencephalon

junction the DTB runs ventrolateral to the periventricular
grey of the third ventricle.

Dopaminergic All cells of

the caudal thalamus have been observed to project axons
into the DTB.

The DTB then courses through the hypothala-

mus giving rise to several branches that innervate the
thalamus (Lindvall et al ., 1974)

~

Past the hypothalamus

the DTB merges with the medial forebrain bundle.

Shortly

before the DTB joins the medial forebrain bundle, it
gives rise to fibers that run with the nigrostriatal DA
system.
(c) The periventricular system:
The periventricular system is composed of two
subsystems, the dorsal periventricular system (DPS) and
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the ventral periventricular system (VPS).

The DPS extends

from the periventricular and periaqueductal grey of the
medulla oblongata through the pons and mesencephalon to
the rostral portions of the diencephalon and septum.

Some

of the cells of origin are located in the locus coeruleus
and are quite different from other catecholamine systems.
Many of the cell bodies are distributed diffusely from
the pons through the mesencephalon to the posterior thalamus.

In addition, fibers from the cell groups A2, A4, and

area postrema may be present (Dahlstrom and Fuxe, 1964).

This

system has been shown to project to the medial thalamic,
epithalamic, pretectal, and hypothalamic regions.

Projec-

tions to the tegmental radiations, medial forebrain bundle,
and dorsal raphe nucleus have also been demonstrated.
Lindvall and Bjorklund (1974)

have

suggested that this

system is composed of relatively short fiber systems that
originate at different levels of the OPS and run for some
distance along the bundle to terminate either locally in
the central grey or at higher levels.

This system, they

suggest, can be regarded as an adrenergic component of
the dorsal longitudinal fasciculus.

(The dorsal longitudi-

nal fasciculus carries fibers from the dorsal tegmental
nucleus.

Their function seems to be a rhinencephalic

relay to brain stem nuclei.)
The second periventricular system, the VPS, is
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less well defined.

It is formed at the meso-diencephalic

junction from converging tegmental radiation fibers as is
the medial forebrain bundle.

It is believed to run from

the interpeduncular nucleus rostrally to the mamillothalamic tract.

At this location, fibers from the median

forebrain bundle join the VPS.

The VPS then moves dorsal-

rostrally through the posterior hypothalamic area where
fiber from the DPS join to form a broad ascending hypothalamic catecholamine system which seems to serve as a
connection between the dorsomedial and paraventricular
hypothalamic nuclei.
(d) The medial forebrain bundle (MFB)
The MFB is a heterogeneous system containing both
NE and DA pathways.

Caudally, the MFB is formed at the

meso-diencephalic junction in the area medial to the
substantia nigra from fibers in the tegmental radiations
(as previously stated these include fibers from the DTB,
CTT, and the DPS).

The converging fibers give rise to

the ascending MFB system.

Fibers from AlO, the mesolimbic

DA system, and the AS and A9 cell groups, and substantia
nigral system, are also present.

Lindvall et al. (1974)

suggested that the substantia nigra DA projection through
the MFB courses to the limbic cortex.

At the rostral

level of the hypothalamus the DTB joins the MFB.

Reflect-

ing their diverse origins the NE fibers of the MFB have
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widely varying terminations to most brain regions.

Those

fiber tracts are discrete when entering the MFB, remain
together in this fiber bundle.

For additional information

on the numerous MFB projections see Lindvall and Bjorklund
(1974).
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Anesthetic Agents:
Ketamine
Ketamine, a phencyclidine derivative, is a shortacting intravenous or intramuscular anesthetic.

Ketamine

is unusual in the type of anesthesia elicited, and unique
in that it is the only clinically available drug in its
class.

This agent is considered to be a

11

disassociative

anesthetic .. and is termed such because it produces a
state of central detachment from the environment.
Ketamine is generally a rapid acting anesthetic
producing a state characterized by profound analgesia,
catatonia, normal pharyngeal-laryngeal reflexes, normal
or slightly enhanced skeletal muscle tone, cardio-vascular
and respiratory stimulation and occasionally a transient,
minimal, respiratory depression.
functions are largely unaffected.

Autonomic and reflex
Airway preservation,

by maintenance of normal respiratory reflexes, and
respiratory stimulation permits short procedures to be
done with relative ease without the need for mechanical
ventilation (Doubrava and Larson, 1971 ).
The action of ketamine on the cardiovascular
system is mediated by three proposed mechanisms; first,
there is a general stimulation of the central vasomotor
center; second, a peripheral release of norepinephrine,
and third, there is evidence that baroreceptor activity
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is decreased, resulting in the increased blood pressure
and heart rate.
The dose of ketamine needed to produce surgical anesthesia is related to the developmental stage of the central
nervous system.

This is not only true phylogenetically,

but is also true in man where a larger dose is needed in
young children than in adults (Doubrava and Larson, 1971 ).
In view of the disassociative state produced by this
anesthetic and its phylogenetic dose relationship, it
has been presumed that the sensory isolation must occur
in the association areas of the brain (Doubrava and Larson,
1971).
Toxicity of ketamine develops in rats at a dose
100 X the anesthetic dose, and in humans at approximately
20 X the anesthetic dose.

Toxic doses of ketamine are

capable of uncoupling the excitation contraction process
of the cardiac muscle and triggering CNS convulsions
which can result in death.
Ketamine

is

rapidly absorbed

and distri-

buted into most body tissues with relatively higher
concentrations in body fat, liver, lung and brain. It is
known not to be metabolized in the brain (Cohen and
Trevor, 1974) and believed mainly to be N-demethylated
and hydroxylated in the liver to form water soluble
products.

Ninety-one percent of an intravenous ketamine
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dose can be recovered in the urine in the form of
metabolites.

These metabolites are less than l/6th as

potent as ketamine itself and are believed not to
contribute to the anesthetic effects (Doubrava and
Larson, 1971 ).

Repetitive ketamine injections do not

produce visible tachyphylaxis.

A 5-fold increase in

ketamine metabolism caused by enzyme induction with
phenobarbital and a 35% prolongation of ketamine's half
life caused by microsomal enzyme inhibition with SKF-525-A
have been shown not to affect the duration of anesthesia
(Cohen and Trevor, 1974).

Termination of anesthetic

action is considered to be due to redistribution, as is
the case for the short-acting thiobarbiturates.
The use of ketamine for anesthesia is accompanied
by a risk of CNS excitation in the post anesthetic period.
This CNS excitation is termed
phenomena

11

and

11

emergence excitatory

includes restlessness, agitation,

increased motor activity, crying, screaming, and visual
hallucinations (Domino et al., 1965; Becsey et al.,
1972).

These side effects have added great impetus to

study the effects of ketamine on central neurotransmitter
systems.

Specifically the catalepsy and hallucinogenic

effects of this drug have stirred a fortuitous interest
in these central neuronal

systems~

adrenergic, and serotonergic.

i.e., the cholinergic,

Literature on catalepsies
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and movement disorders continually suggests that these
defects may be related to a cholinergic-dopaminergic
imbalance (Arvidsson et al ., 1966; Munkvad et al., 1968;
Corrodi et al ., 1972).

Serotonin and tryptamine have also

been considered to play a role in catalepsy as demonstrated
by intracerebral injections (Michaux, 1962; Ernst, 1969).
Hallucinations and central excitation alone and associated
with psychotropic drugs have been tentatively linked with
the noradrenergic and serotonergic systems (Sulser and
Sanders-Bush, 1971; Weiss and Laties, 1969; Schildkraut
and Kety, 1967; Snyder et al ., 1970b; Sung et al., 1973).
With regard to the adrenergic system, several ketamine
effects have tentatively been identified.
It has been generally accepted that the adrenergic
neuronal reuptake system, a high affinity neuronal transport system for NE, functions as the primary means of
terminating the biologically active neurogenically
released transmitter at peripheral and central synapses
(see Iversen, 1971).

This type of high affinity system

is not unique to NE containing neurons.

Similar systems

have been described in brain for neurons containing DA
(Snyder and Coyle, 1969), gamma-aminobutyric acid (GABA)
(Iversen and Neal, 1968), and serotonin (5-HT) (Shaskam
and Snyder, 1970).

Several studies have assessed

ketamine's ability to block these specific reuptake
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systems and therefore potentiate transmitter action.
smith et al. (1975) demonstrated in vitro in rat cerebral cortex tissue that ketamine competitively inhibited
the high affinity transport system for the uptake of NE
into adrenergic nerve terminals.

Ketamine, in vitro,

also was found to cause release of stored NE.

However,

ketamine's potency in this respect was estimated at
l/15 the potency of desmethylimipramine, suggesting
minor physiologic significance to this action.

This

same group more recently assessed ketamine's in vitro
ability to block uptake of OA, GABA and 5-HT and compared ketamine's relative potency on each system.

Smith

et al. found ketamine to be most effective in blocking
5-HT reuptake and l/4 as effective in blocking NE and
DA reuptake.

GABA was least affected (Azzaro and Smith,

1976).
Phencyclidine, the parent drug of ketamine,
failed to gain clinical usage due to a very high incidence
of the post anesthetic emergence phenomena.

It is of

interest to note that ketamine, which is considerably less
potent than phencyclidine in its behavioral effects, is
also about 100 times less potent than phencyclidine in
inhibiting synaptosomal NE uptake (Smith et al ., 1975).
It has now also been demonstrated that phencyclidine
inhibits DA and 5-HT synaptosomal uptake in approximately
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the same proportion (Smith et al ., 1975).

Even though

ketamine has been demonstrated to competitively block
reuptake of these amines, ketamine is not actively
accumulated in rat brain slices (Cohen and Trevor, 1974).
Ketamine's effect on central DA metabolism was
first examined on whole brain samples.

These early

studies report no change in endogenous DA levels following
ketamine.

More recent studies, realizing that endogenous

levels may be maintained with marked changes in amine
metabolism (turnover), have also measured DA's major
metabolite, homovanillic acid (HVA).

A rise in this

metabolite is believed to indicate an increase in central
DA activity; a fall in this metabolite is taken to mean
a decrease in central DA activity (Cooper et al., 1974).
Unfortunately most of the data was derived from whole
brain studies which limits their value.

Biggio et al.

(1974) found ketamine does not influence whole brain DA
levels, however, he reported finding a significant
increase in HVA at 60 minutes post ketamine administration
and suggested the possibility of an increase in DA turnover.

Sung et al. (1973), using enzyme inhibition to

estimate DA turnover, found that 40mg/kg of ketamine
resulted in a decreased rate of turnover at two hour post
ketamine administration followed by increased turnover
four and six hours post administration.

The turnover rate
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at six hours post ketamine administration was elevated
200%.

Although the duration of anesthesia was not

reported, it might be assumed from the given dose and
animal species that this large increase in turnover
occurred approximately five hours post anesthesia.

The

relevance of this increase in turnover to anesthesia
should be questioned.

In 1976, Glisson et al. reported

endogenous NE and DA levels in rat whole brain and select
brain regions of rabbit.

Again, it was demonstrated that

no effect of ketamine could be seen in whole brain on
endogenous amine levels; however, in select areas ketamine
caused a significant rise in DA levels at 10 and 30 minutes
post ketamine administration.

Ylitalo et al. (1976)

measured both DA and HVA in rats post ketamine and
reported significant increases in striatal HVA 15 minutes
and 1 hour after ketamine administration.

These values

returned to normal 3 hours post drug administration.
The effects of ketamine on norepinephrine levels
are less consistent than for dopamine.

Norepinephrine

whole brain levels have been reported to increase (Ylitalo
et al., 1976), decrease (Sung et al., 1973), and remain
unchanged (Biggio et al ., 1974) during ketamine anesthesia.
All experiments were carried out on rats; Ylitalo and
Biggio used a lOOmg/kg dose while Sung used a 40mg/kg dose;
in all of these experiments amine levels were examined at
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approximately the same time periods.
Investigators have used drugs known to have effects
on specific central transmitter systems in an attempt to
delineate relationships between these transmitter systems
and ketamine.

Conflicting results have been found with

cholinergic and anticholinergic agents.

Authier et al.

(1972) used the anticholinergic agent procyclidine in
rabbits and found enhanced ketamine-induced catalepsy.
Hatch (1974) found that atropine, another anticholinergic
agent, prevented ketamine catalepsy in dogs, however,
mecamylamine, a ganglionic blocker, was shown to enhance
ketamine catalepsy.

In the case of the serotonergic

system, Monachon et al. (1972) found in cats that
methiothepin, an antiserotonergic compound, prevented
ketamine catalepsy and prolonged ketamine anesthesia.
With respect to the adrenergic system, pimozide, an antidopaminergic compound, was shown by Hatch and Ruch (1974) to
enhance ketamine catalepsy, and more importantly, antagonize ketamine anesthesia.
Other investigations have attempted to localize
ketamine's effect on brain by characterizing and localizing gross changes in electroencephalographic (EEG)
activity.

Ketamine, unlike many other anesthetics, is

epileptogenic in nature.

The increase in EEG activity

resulting from ketamine's epileptic nature make this form
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of study more logical
thetics.
to

than

for

EEG depressing

anes-

Corssen et al. (1968) first suggested ketamine

be a dissociative_ anesthetic based on his findings

that ketamine electrographically dissociated the
neocortex from the limbic system, and the thalamocortical
system from the midbrain

reticular system.

Also of

importance is that this group suggested that ketamine
affected two areas of the brain differentially, the
cerebral cortex and the limbic system.
Of the EEG effects induced by ketamine, theta
activity has been characterized by both Domino et al.
(1965) and Massopust et al. (1972).

The synchronous

theta activity seen in both the thalamus and the neocortex
has led Domino et al. and others to speculate that
ketamine might act on the diffuse thalamic projection
system at either the thalamic or cortical level.

Masso-

pust, on the other hand, has suggested a temporal relationship between theta activity and analgesia from data he
obtained in rhesus monkey.

This group further suggests

that the beginning of theta activity and analgesia
correlates well with anesthetics other than ketamine which
also are potent analgesics (i.e., nitrous oxide and
cyclopropane).
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Halothane
The introduction of halothane into clinical practice has met with unprecedented success.

In an attempt

to find a non-inflammable volatile anesthetic agent
Suckling (1957} examined a number of highly stable fluorinated hydrocarbons which led to the introduction of
halothane.
Halothane is a heavy colorless liquid at room
temperature.

It has a gram molecular weight of 197.39

and a boiling point of 50.2°C (at one atmospheric pressure}.
With a vapor pressure of 241 mmHg at 20°C, halothane is
extremely suitable for vaporization.
Halothane is a potent nonirritating anesthetic
characterized by a low post anesthetic incidence of
complications.

Halothane blood solubility coefficient is

2.3 (blood:gas, partition ratio) resulting in rapid
induction of anesthesia, as compared to ether.

Halothane

does have a moderate affinity for fat, however, considering the relatively low blood flow through adipose tissue,
this affinity becomes important only after prolonged
periods of anesthesia.
Halothane has been shown to have profound effects
on circulation which can lead to moderate or marked
arterial hypotension.

Price (1960} observed decreased

contractile force, stroke volume and cardiac output with
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halothane-oxygen anesthesia.

This myocardial depression

is directly related to the dose of halothane (Mahaffey
et al ., 1961; Wenthe et al ., 1962).

Depression of the

s-A node has been demonstrated by Flacke and Alper (1962).
Like chloroform, halothane sensitizes the ventricular
conducting tissues to the actions of catecholamines
increasing the arrhythmic potential.

Vascular smooth

muscle is also directly affected by halothane.

Direct

vasodilatation has been reported on vascular smooth
muscle in skeletal muscle and skin (Black and McArdle,
1962), as well as splanchnic, hepatic and renal vasculature (Epstein et al ., 1962).

This vasodilatation is

accompanied by a diminished blood flow as a result of
lower systemic pressure.
It has been suggested by Black and McArdle (1962)
that halothane blocks the effects of noradrenaline at its
effector site.

In this way halothane interferes with the

ability of the efferent sympathetic nervous system to
antagonize a fall in systemic blood pressure.
Halothane has minimal neuromuscular blocking
action and therefore at surgical levels must be supplemented by specific neuromuscular blocking agents when good
muscle relaxation is needed.

Slight potentiation of the

non-depolarizing agents and slight antagonism of depolarizing agents has been reported (Katz and Gissen, 1967).
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Shivering is common during post anesthesia recovery and
is attributed to heat loss presumably from cutaneous
vasodilation.
One obvious disadvantage of halothane's clinical
use for surgery is that it is a relatively poor analgesic
agent.

For this reason, halothane is usually supple-

mented with nitrous oxide.
To a large extent halothane is eliminated
unchanged through the lungs.

It has been estimated

that a minimum of 60% of administered halothane is
eliminated unchanged within 30 hours.

Up to 20% is

metabolized by the liver microsomal enzyme system and
excreted in the urine (Van Dyke and Chenoweth, 1965).
The toxicology of halothane stems from halothane's limited metabolism.

Hepatic damage as a result

of halothane anesthesia is believed to result from an
accumulation of metabolites in the liver.

As of yet,

the toxic metabolite or metabolites have not been
identified.

Halothane has been shown to undergo both

oxidation and dehalogenation to form trifluoroacetic
acid and bromide and chloride radicals.

Stenger and

Johnson (1972) have pointed out that animals pretreated with phenobarbital, which caused induction of
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microsomal enzymes and therefore increased the fraction
of halothane metabolized, increased hepatic damage as
well.

More recently, it has been suggested by Van Dyke

(1978) that in the presence of low oxygen tension the
pathway of metabolism of halothane is altered resulting
in the formation of toxic intermediates.

This toxicity,

however, is relevant to chronic rather than acute
exposure.
The relationship of central catecholamine function
to halothane anesthesia has been studied primarily from
two directions:

(a) halothane's effect on catecholamine

metabolism; and (b) the effect of pharmacologically
altered amine metabolism on halothane anesthesia.
(a) Halothane's effect on central amine metabolism:
Nikki and co-workers (1971) found halothane to
increase rat whole brain DA levels and decrease 5-HT
levels without altering brain NE levels after 30 minutes
of anesthesia.

Anden et al. (1974) found no effect of

halothane or pentobarbital anesthesia on rat whole brain
DA metabolism or turnover.

This group also investigated

anesthetic effects on haloperidol-induced increase in DA
turnover.

In rat whole brain, these authors demonstrated

that pentobarbital but not halothane resulted in a
decrease in whole brain DA turnover.

Ngai et al. (l969a)

reported that halothane had no effect on NE or DA turnover.
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However, he did report a decrease in the NE rate constant
with a concomitant increase in endogenous content suggesting altered NE metabolism.

Consistent with this finding,

Li et al. (1964) showed an increase in NE content in the
heart with halothane anesthesia.

Further support comes

from Persson and Waldeck (1971) who reported a decrease
in whole brain NE turnover with halothane and Lidbrink et
al. (1972) who demonstrated a similar effect in the neocortex.
Ngai et al.

(1969b)

also investigated halothane•s

effect on neuronal uptake; unlike ketamine, halothane did
not significantly alter this process.
(b) Altered amine metabolism and MAC:
The minimum alveolar concentration of an anesthetic (MAC) necessary to prevent movement in response to
a painful stimulus in 50% of the subjects tested, has
proven to be the most readily measurable and accurate
index of anesthetic potency for inhalation anesthetics
(Markel and Eger, 1963; Eger et al ., 1963).

Alterations

in potency of an inhalation anesthetics are readily
measured in terms of altered MAC.
Sympathominergic drugs have been studied in
relation to anesthesia for a multiplicity of reasons.
Of interest to many has been the altered states of
central nervous system excitation produced by amphetamines,
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catecholamines, depleters (reserpine), and precursor
therapy (L-DOPA) in relation to anesthesia.
The effect of both acute and chronic amphetamine
administration has been evaluated on halothane MAC.
Acute administration of amphetamine at doses of 0.1 to 1.0
mg/kg were shown to increase halothane MAC in dogs from
20% to 100% above controls in a dose related manner.

In

contrast, chronic doses of 5 mg/kg over a seven day period
produced a 21% decrease in halothane MAC over control
(Johnston et al ., 1972).

Johnston and colleagues (1974),

in a further attempt to relate these changes to catecholamine function, used alpha-methyl-p-tyrosine (AMPT),
reserpine, and parachlorophenylalanine (PCPA) in conjunction with amphetamine and determined halothane MAC.

They

found that pretreatment of dogs with either reserpine
or AMPT greatly reduced the amphetamine precipitated
increase in halothane MAC, while PCPA, a drug affecting
serotonin, had no effect, suggesting that catecholamines
and not serotonin were responsible for the amphetamineinduced increase in halothane MAC.

Reserpine and AMPT,

catecholamine depleters, were shown to decrease halothane
MAC when used alone.
L-Dopa, a precursor for both central adrenergic
transmitters, DA and NE, when administered results predominantly in an increase in DA rather than NE (Everett and
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Brocherding, 1970; Liu et al., 1971)

Johnston et al.

(1975) found that both acute and chronic L-dopa in doses
of 5 to 25 mg/kg reduced halothane MAC in a dose dependent
fashion.

In view of these results Battista et al. (1973)

and Johnston (1975) suggested the decrease in halothane
MAC to be a result of increased central inhibition as a
consequence of increased DA central content.

This group

further suggests that NE is excitatory in nature centrally
and therefore an increase in NE centrally results in an
increased halothane MAC.
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Nitrous Oxide
Nitrous oxide (N 2o), one of the first known
anesthetic agents, was first prepared by Priestly in 1776.
Not until 1868 did its use become fashionable in clinical
practice when Andrews combined oxygen with nitrous oxide
to lay the foundation for its present day use.
Commercially, nitrous oxide is produced by heating
ammonium nitrate to a temperature above 245°C, which
results in two products, N20 and H2 0. Many of the early
toxic effects attributed to N20 were shown to be a result
of ammonia and nitric acid impurities.

As a result,

commercially obtained N20 is carefully processed to a high
degree of purity and marketed in steel cylinders under
pressure in a liquid state.
At room temperature and one atmospheric pressure,
N o is a colorless, sweet smelling and nonirritating gas.
2
Nitrous oxide is neither inflammable nor explosive but
will support combustion of other agents, even in the
absence of oxygen, due to its decomposition at temperatures
over 450°C to oxygen and nitrogen.
The blood/gas solubility coefficient of nitrous
oxide is 0.47.

It is rapidly absorbed from the alveoli

and does not combine chemically within the body and is
therefore eliminated as rapidly as it is absorbed (Dripps
et al., 1972).
Today more general anesthesia techniques are based
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on the use of nitrous oxide than on that of any other
single agent (Dripps et al ., 1972).

Although N20 is a

potent analgesic agent, it lacks potency as an anesthetic
agent.

Smith (1971) has estimated that a 101% concentra-

tion would be needed for 1 MAC (as compared to 0.74 for
halothane), however, 20 volumes %is reported to be
equivalent to 15 mg of morphine sulphate in analgesic
effectiveness (Goodman and Gilman, 1975).
Nitrous oxide has gained wide clinical acceptance
for current day anesthesia.

This can be attributed to

nitrous oxide's analgesic ability and more importantly
its capacity to significantly reduce the amount of
volatile inhalation anesthetic needed to achieve adequate
levels of anesthesia.

Munson et al. (1965) reported that

a 72 percent alveolar concentration of the N20 reduced
the MAC of fluroxene anesthetic over 75% (i.e., from 3.4
to 0.8%).

Saidman and Eger (1964), using a 65% concentra-

tion of nitrous oxide, found a 60% reduction in halothane
MAC.

This increases the clinical margin of safety and

effectively decreases the toxic side effects of these
potent volatile anesthetic agents.
As mentioned previously, toxic effects attributed
to N 0 in the early literature have been found to have
2
resulted from impurities. Current day manufacturing
standards have resulted in nitrous oxide gaining the
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reputation of the least toxic gas anesthetic available
(Wytie and Churchill-Davidson, 1972).
believed not to be metabolized in vivo.

Nitrous

oxid~

is

It is eliminated

through the lung (90%) as well as through the skin (10%).
various forms of anoxia have been reported in conjunction
with nitrous oxide use.

Two causes have been cited.

First, when nitrous oxide is used alone in concentrations
above 80%, required oxygen content of 20% cannot be
provided.

Second, diffusion hypoxia occurs when concen-

trations above 75% of nitrous oxide are used over long
periods of time (over 90 minutes).

During anesthesia

recovery, rapid elimination of nitrous oxide through the
lungs can result in decreased oxygen availability if
inspired oxygen concentration is not kept above 25% (Fink,
1955; Frumin and Edelist, 1969).
The amount of research dedicated toward exploring
the central mechanisms of nitrous oxide has been surprisingly small.

This fact may be attributed to nitrous

oxide's lack of potency.
Investigation into nitrous oxide's effect on
monosynaptic and polysynaptic spinal reflex actively has
shown each to be depressed approximately to the same
degree (de Jong et al ., 1967; de Jong et al ., 1968b).
Although research initially suggested the spinal cord as
a possible site of analgesic action by nitrous oxide,
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later studies by the same investigators in decerebrate
cats with intact spinal cords and without the use of an
anesthetic agent such as halothane, as was used in initial
experimentation has shown only slight effects on spinal
cord synaptic transmission (de Jong et al ., 1970).
The cardiovascular system has been shown to be
relatively unaffected by nitrous oxide.

At high levels

of nitrous oxide a decrease in ventricular contractile
force in a sympathectomized preparation was demonstrated
by Craythorne and Darby (1965).

In the nonsympathectomized

animal a reflex increase in sympathetic tone results with
nitrous oxide; however, no effect was seen on blood
pressure, cardiac output, or stroke work.

Additional work

by Lundborg et al. (1966) demonstrated an increase in
peripheral vascular resistance with nitrous oxide suggesting that nitrous oxide exerts only reflex stimulation of
the sympathetic nervous system.

Recent publications indi-

cate that nitrous oxide, in the presence of halothane,
results in increased sympathetic activity mediated from
suprapontine origins.

In fact, when cats were sectioned

midcollicularly, nitrous oxide had a depressant effect
on peripheral sympathetic activity (Fukunaga and Epstein,
1973).

It is of interest to note that this effect was not

found when enflurane, another volatile halogenated anesthetic, was used (Smith et al ., 1978).
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The relationship of limbic neuronal firing to
nitrous oxide-oxygen anesthesia has been examined by
Babb et al. (1975), in seven patients implanted with
fine wire microelectrodes.

Unlike ketamine which has

been shown to increase limbic neuronal activity, or
sodium thiopental which has been shown to decrease
limbic neuronal activity, nitrous oxide was shown to
have little or no effect on limbic neuronal activity
as shown by electroencephalographic activity.

Impor-

tantly; this suggests that different anesthetics may
have several different mechanisms of action on synaptic
transmission in the central nervous system (Babb et al .,
1975; Galindo, 1975).

Babb further suggests that

thiopental enhances the activity of central inhibitory
interneurons.
Nitrous oxide analgesia has been compared experimentally to analgesia produced by aspirin, alcohol
and narcotics in an attempt to characterize its nature.
Unlike aspirin and alcohol, nitrous oxide resembles
pharmacologically the opiates in inhibition of pain.
Nitrous oxide analgesia is reversible in a dose related
fashion (5-30 mg/kg) by naloxone; its euphoric action
can also mimic narcotic euphoric effects (Berkowitz et
al., 1977).

Berkowitz and co-workers have suggested

three important areas of research needed to help clarify
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mechanisms of analgesia:

(1) Alterations in metabolism

of NE, DA or 5-HT; (2) Alterations of receptors or post
synaptic events in relation to these or other transmitter
systems; (3) Release mechanisms for the endogenous opiate
like substances, endorphine and enkephalin, need to be
established in relation to the stated transmitter systems.

CHAPTER II
METHODS
Animals
Specific animal needs of the research involved in
this dissertation required:

(1) that the animals be easy

to handle, (2) that they have large lateral ventricles
adequate in size to facilitate intraventricular administration of 14c-tyrosine necessary for isotopic determination
of catecholamine turnover, (3) that the brain size be
sufficiently large so that the catecholamines could be
assayed on brain regions of a single animal in order to
avoid the increased error encountered when brain parts are
pooled, (4) and lastly, for administration of the volatile
inhalation anesthetics, animals large enough for tracheal
intubation were needed.

To meet these specific require-

ments, adult male albino New Zealand rabbits were chosen.
Male animals were used exclusively to prevent possible
estrus effects on the experimental results.

Animals were

obtained from a single breeding source, as it has been
shown that turnover levels can be significantly affected
when different sources are used (Costa, E., 1971 ).

All

animals were housed in individual rabbit cages located
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within the Animal Research Facility.

These facilities

are maintained at 22 degrees Centigrade with a 12 hour
alternating light-dark cycle.
provided to the animals ad lib.

Food and water was
All animals were housed

in these conditions for 2 .weeks prior to use.

The brain

areas used in this study were the mesencephalon, thalamus,
hypothalamus, and cortex.
because:

These areas were chosen

(1) they have sufficient content of the amines

under study to prevent the necessity of brain part pooling,
(2) they are major anatomical subsections of the brain,
and (3) for literature comparison, these areas are frequently studied.
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Basic Turnover Techniques
In establishing the turnover techniques to be
used in this dissertation, many turnover methods were
considered (e.g., Isotopic:

Labeling of stores with

either labeled precursor or labeled transmitter; Nonisotopic:

Inhibition of biosynthesis or measuring end product

formation (Costa and Neff, 1970)).

After an in-depth

evaluation of all methods available, the isotopic trace
precursor method was found to be the most reliable.
Basic to this measure of turnover is the metabolic
pathway of endogenous catecholamine synthesis (cf. Figure
#1).

L-tyrosine, the precursor to both DA and NE, enters

the central nervous system (CNS) by transversing the
blood-brain barrier.

Once in the nerve cell, L-tyrosine

is converted to L-3,4-dihydroxyphenylalanine (L-dopa)
by the enzyme tyrosine hydroxylase.

This conversion of

tyrosine to L-dopa is considered to be the rate limiting
process which controls the amount of transmitter synthesized by the nerve cell, L-dopa is then converted to
dopamine and/or norepinephrine depending on whether the
cell is dopaminergic or noradrenergic in nature.
11

During

steady state 11 neuronal activity, the amount of NE or DA

synthesized is considered to be equal to that degraded
(Costa, 1971), thus a constant endogenous 1 evel of
neurotransmitter is maintained.

It is important to

,

r
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Diagram of the biosynthesis of dopamine and

Figure #1

norepinephrine in the central nervous system.

Tyrosine,

which is permeable to the blood brain barrier, is supplied to the brain from the blood.
tyrosine (

14

Radioactively labeled

c-L~Tyrosine) is introduced intraventricularly

and is subsequently metabolized in vivo to labeled dopamine
and norepinephrine and to their respective metabolites
parallel to the non-labeled endogenous amines.
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understand that basic to the concept of turnover is the
primary assumption that the amount of transmitter released
(neuronal activity) is proportional to the amount degraded.
Since the amount of transmitter formed is equal to that
degraded, it has been ascertained that both synthesis and
degradation are proportional to transmitter release.
These premises are the foundation upon which the concept
of turnover has been established (Costa, 1971; Costa and
Neff, 1970; Cooper et al., 1974).

As described, turnover

is an estimate of neuronal activity, is based on steady
state kinetics, and is calculated from the rate of
synthesis or degradation of the transmitter under study.
Preliminary Studies:
Initially several preliminary studies were
undertaken to establish dopamine and norepinephrine
turnover methodologies which would be of sufficient sensitivity so that individual brain parts could be used
without brain pooling and to be able to determine dopamine and norepinephrine turnover in four brain regions
simultaneously.

After careful screening, an isotopic

precursor method was chosen using labeled L-tyrosine for
the precursor (used because it precedes the rate limiting
enzymatic step that controls the synthesis rate).
Two commonly used isotopically labeled tyrosine
forms are available, 3H and 14c.

3H-tyrosine has a higher

57

specific activity than 14c-tyrosine, however, the 3H atoms
easily exchange with H+ atoms particularly at a low pH.
This makes the 3 H labeled form unreliable for use in
these experiments which required acid extraction.

The

14c-L-tyrosine form was found to be stable at low pH and
used throughout these experiments (483 mCi/mmol, AmershamSearle Co.).
The intraventricular injection technique used was
previously described by Glisson (1971).

Dye and isotopic

distribution using the intraventricular injection route
showed an
... acceptable distribution to all brain areas
under study and was identical to that reported by Glisson
(1971).

It should be noted that initially the caudate
nucleus was to be included in this study, however, it was
found that this brain area, which is in juxtaposition to
the isotopic injection site, had an unacceptable difference in isotope concentration between the left and right
sides.

The magnitude of such unequal isotopic distribu-

tion for this particular area would result in an erroneous
determination.
Based upon results of preliminary trials the
following procedure for isotopic intraventricular injection was adopted:

Four hours before the turnover

experiment, each animal was gently restrained and the hair

·r~

.,
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clipped from the top of the head.

!.

Lidocaine (1%) was

injected intradermally into the scalp (0.25cc).

The

analgesic field was tested by a pin prick; in the
absence of analgesia the animals blink.

After the loss

of pain sensation midline longitudinal incision was made
through the scalp exposing the skull.

Bone wax was

applied to the skull to stop any bleeding from the bone.
The coronal and sagital sutures were visualized.

Using

dividers a point 4.0 mm caudal to the coronal suture and
4.5 mm lateral to the sagital suture was identified and
marked.

A small hole was then made using a blunted 18

gauge needle by gentle hand rotation.

Special care was

taken never to penetrate the dura mater.
then applied to seal the hole until
ventricular injection.

tim~

Bone wax was
of the intra-

The surgical procedure itself

produced no signs rif stress during or after establishing
the intraventricular injection site.

The animals were

then left undisturbed until the start of the experiment.
Intraventricular injections were made through the
injection site using a 250

~1

syringe fitted with a blunt

27 gauge stainless steel needle 6 mm in length. Using
gentle pressure, two and one half ~Ci of 14 c-L-tyrosine
was delivered slowly in a 50

~1

volume.

Once the isotope

was delivered the hole was immediately resealed with bone
wax.

All injections were visually confirmed for

i~l

II!

I
,,,.

j
~
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intraventricular placement during dissection of the brain.
This type of injection is referred to as delivering a
11

pulse dose.

11

The amount of L-tyrosine injected into each

rabbit was 883 ng.

The quantity of isotopic tyrosine

injected in proportion to the whole brain content of
tyrosine must be minute so that the endogenous tyrosine
pool is not significantly altered.
frequently referred to as a

11

This small amount is

trace dose.

11

Generally the

above described technique is referred to as an isotopic
~lse

intraventricular trace precursor technique (Costa,

1971).

14 c-L-tyrosine enters the metabolic scheme as is
14
shown in figure #1. The rate of synthesis of
c-L-DOPA
14
from
c-L-tyrosine parallels that of endogenous L-DOPA
from endogenous L-tyrosine.

The labeled transmitter

synthesized is stored and released from the granular
pool as is the endogenous transmitter (Costa, 1971;
Costa and Neff, 1970).

The rate of synthesis, or

degradation, can be determined by measuring the content
of labeled transmitter in whole or brain parts at
different time periods (Brodie et al ., 1966; and figure
#2).

For these determinations, specific portions of the

synthesis or degradation curves are used.

The degradation

slope (run off slope) is best suited for turnover determination due to its long stable exponential decay.
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Figure #2

Diagramatic representation of a typical

exponential isotopic catecholamine run off slope as
determined by sampling the isotopically labeled
dopamine or norepinephrine in brain regions at the
four designated time coordinates.
per minute I

~ram

When disintegrations

(DPM/Gm) are plotted against time

an exponential function is found (above).

When the

DPM/Gm values are converted to natural logarithm and
plotted, a straight line function is derived (below).
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Preliminary studies demonstrated that run off slopes
varied in time with different brain regions.

Based upon

the results, four time periods were chosen which allowed
for the simultaneous turnover measurement of dopamine and
norepinephrine in the four brain areas used.

These time

coordinates were 40, 55, 90, 105 minutes.

Turnover Calculations:
Calculation of turnover is based on two factors:
(1) the "rate constant" as determined by the run off
slope and (2) the level of endogenous transmitter.

The

rate constant is defined as the fraction of the neurotransmitter pool that is lost per unit time and is
frequently referred to as the "fractional rate constant"
(for additional information see Brodie et al ., 1966; Costa,
1971).

Once the rate constant and endogenous amine level

have been determined, turnover is then calculated as the
product of the rate constant times the endogenous level.
The limiting problems concerning measurement of
catecholamine turnover in vivo involve:

(1) establishment

of steady state conditions, (2) the number of time points
that can be measured in a single animal, (3) unknown
cytological factors, (4) enzyme and substrate controlling
mechanisms are not fully understood, to name a few.

A

comprehensive discussion of these and other limitations
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can be found in articles by Costa (1971) and Costa and
Neff (1970).
']!

ii
!i
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Specific Methodologies
The specific methodologies used in this dissertation to measure dopamine and norepinephrine turnover in
the various brain areas are as follows.

All experiments

were started at approximately 9:30 a.m. to minimize
chronobiological variation.

A total of 52 animals was

used to establish the awake control data.

Four animals

were used for each run, where one animal was used for each
time period.

Awake control subgroups were staggered

between each anesthetic series to help control for
seasonal variation.

In each anesthetic group sixteen

animals were used, four at each time period.

Tissue Samples:
Animals were sacrificed by decapitation.

The

brains were removed rapidly, rinsed well with saline to
remove excess isotope and placed on an ice cold petri
dish for dissection.

Surface blood vessels and connective

tissue were removed.

The left and right cerebral hemi-

spheres were separated.

A cut was made through the left

and right cerebral peduncles, freeing the left and right
hemispheres.

With careful teasing, the hippocampus was

removed exposing the caudate nucleus from head to tail.
Using a pair of toothed iris forceps, the caudate nucleus
was teased away from the ventricular wall.

A cut just
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lateral to the internal capsule was made to remove the
lenticular nuclei.
as cortex.

The remaining tissue was considered

Next, the midbrain-diencephalon region was

obtained by transecting the lower brain stem on a line
from the caudal end of the inferior colliculus to the
rostral end of the pons, thereby isolating the midbraindiencephalon from the rest of the brain stem.

The

midbrain was separated from the diencephalon by a transverse cut.

The diencephalon portion was cut transversely

to facilitate dissection of the thalamus and hypothalamus.
A transverse section was made separating the dorsal
thalamus from the more ventral hypothalamus.

These

dissections were easily made and identical areas were
always removed as demonstrated by the consistent brain
part weights (See Appendix A).
Catecholamine extraction:
Immediately following removal, each tissue was
weighed and placed in a 15 ml ground glass homogenizing
tube containing 6 ml ice cold 0.4 N perchloric acid, 0.02%
ascorbic acid and 0.2% EDTA.

The tissue was thoroughly

homogenized and poured into a 15 ml thick walled conical
centrifuge tube stored on ice.

An additional 2 ml of

0.4 N perchloric acid were added to the homogenizing
vessel as a wash and then transferred to the centrifuge
tube.

The tubes were placed in a

r~frigerated

centrifuge
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held at 0°C and centrifuged for 20 minutes at 3200 x g.
Following centrifugation, the supernatant was filtered
using Whatman #1 filter paper.

The pellet was resuspended

in 2 ml of ice cold 0.4 N perchloric acid and centrifuged
for reextraction.

The supernatant was filtered and

combined with the original supernatant.

The tubes were

sealed and stored frozen (-25°C) until catecholamine
separation by column chromatography (Glisson, 1971).
Column preparation:
The column assemblies were adapted from 1.0 ml
disposable syringes.

It was necessary that the internal

diameter of the syringe barrel be 4.2 - 4.5 mm.

The upper

lip of the syringe was cut off and a 2 em piece of tygon
tubing affixed to the top of the syringe barrel in such
a way that one centimeter of tubing extended above the
top of the barrel (Glisson, 1971).

This

11

COlumn assembly.,

was then submerged in a beaker containing distilled water.
It was necessary that the actual packing of the column
with resin be done under airtight conditions, as air
bubbles will disrupt the uniform packing of the resin.
Air bubbles were removed from the empty column assembly
by inserting a stirring rod inside the column and working
it up and down a few times.

With the column completely

filled with water, a small ball of Pyrex glass wool was
inserted into the column and forced to the tip with a
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stirring rod.

This piece of glass wool serves to trap the

resin within the column.

A G 50w X 4 200-400 mesh resin

cleaned and cycled to the H+ form was suspended in 0.01 M

II~

phosphate buffer and 0.1% EDTA and placed in a 2ml pipet.
The tip of the filled pipet was inserted under water into
the tygon tubing attached to the top of the column.
resin was then allowed to flow into the column.

The

~

f

I

After

the resin bed had settled to a height of 50mm, another
ball of Pyrex glass wool was inserted into the top of the
column.

The freshly packed columns were then mounted onto

the column board.
The column board consisted of 20ml graduated glass
syringes mounted through a horizontal board attached to
ring stands.

A plastic 3 way stopcock was attached to the

tip of this syringe.

To the side of this syringe, a 20ml

syringe barrel was mounted in a similar fashion.

This

barrel served as a reservoir through which the tissue
extract and other reagents could be added to the column.
The reservoir and syringe were
of plastic stopcocks.

connected through a series

On the open end of the stopcock

attached to the glass syringe, a plastic fitting was
placed.

The fitting allowed for an air-tight seal to be

made between the tygon tubing on the resin column and the
stopcock on the glass syringe.

I:.,

!

1.

The fitting was made by

removing the metal insert of a disposable needle and using
I.

,'

:I
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the upper plastic portion as the fitting.

Prior to the

attachment of the freshly packed resin column, distilled
water was added to the reservoir and drawn through the
stopcock assembly into the syringe to remove any air from
the system.

With the distilled water slowly dripping

through the stopcock, the resin column was seated tightly
on to the stopcock fitting.

The column was mounted in

such a way as to allow for liquids to be drawn into the
glass syringe from the reservoir and then to flow through
the resin column.

With the resin column mounted on the

column assembly, the resin was then cycled from the H+
form to the Na+ form by passing 20 ml O.lM sodium phosphate buffer containing 0.1% EDTA at pH 6.5 through the
resin column at a flow rate of one drop every 10 seconds
(.3mls/min)(Glisson, 1971 ).

After the buffer had passed

through the column the pH of the effluent was checked.
A pH of 6.5 indicated that the column was cycled and
ready to receive the tissue extract.
Catecholamine Ion Exchange Column Chromatography:
Before adding the tissue extract to the column,
the pH was adjusted to 6.5 using 10 N potassium carbonate.
A digital pH meter, magnetic stirrer and an automatic
buret were used.

At pH 6.5, potassium perchlorate

precipitates out of the neutralized extract.

Placing the

neutralized samples into a refrigerator for 10 minutes
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increases the precipitation rate.

Following cooling, the

extract was centrifuged at 1500 g for 10 minutes to pack
the precipitant.

The supernatant was poured into the

reservoir of a column assembly.

The extract was drawn

into the glass syringe and allowed to flow through the
resin at a rate of one drop every 10 seconds.

After the

extract passed through the column, the resin was washed
with 40 mls of distilled water.

The flow rate for the

water wash was twice as fast as that of the tissue extract.
Care must be taken in handling the water wash as well as
all column effluents, as the water will contain consider14
able amounts of
C products washed from the resin.
Following the wash, 1 N hydrochloric acid was added to
the reservoir.

During the elution and fractionation of

the norepinephrine and dopamine (isotopic and endogenous),
the flow rate for the hydrochloric acid (HCl) was again
controlled at 1 drop every 10 seconds.

The first 3.5 ml

HCl passed through the column was collected and discarded
by appropriate isotopic waste procedure.

The next 6 mls

of acid passed through the column containing the norepinephrine were collected in small shell vials that had been
washed and rinsed in distilled water.

An additional 13 ml

HCl fraction was collected and contained the dopamine.
All vials were sealed and frozen at -25° C until
samples were thawed for further processing.
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Catecholamine quantification:
Before either norepinephrine or dopamine can be
quantitatively measured, they must be converted to their
respective fluorophores.

As fluorophores dopamine and

norepinephrine can be measured using a spectrophotofluorometer.

Since norepinephrine and dopamine are converted

at different optimum pH•s to two different fluorophores,
the method is highly specific for each compound (Carlsson
and Lindqvist, 1962; Carlson and Waldeck, 1958).
The conversion scheme for norepinephrine as
modified from Glisson (1971) is shown in table #1.

Upon

completion of the chemical procedure shown in table #1,
the samples were poured into reading tubes and read in an
AMINCO spectrophotofluorometer equipped with an ellipsoidal mirror condensing system at 400 nM excitation and
505 nM emission wavelengths.

The fluorophore was found

to be stable for one half hour.
within this time period.
insure sample purity.

The samples were read

Spectral curves were plotted to

Maximum sensitivity of these

methods was found to be 500 picogram (NE).

Calculation

of endogenous norepinephrine was done using the mathematical equation as shown in table #2.
For dopamine, it was necessary to develop new
assay techniques to be able to measure the concentrations
in a single brain region.

This was accomplished in two

I
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TABLE #1
Conversion of

Reagent

hrinolutine

Standards
1X
2X

Faded
Blank

Sample

Internal
Standard

H20

3.8

3.7

1.4

1.4

1.3

PO 4
Buffer
0.1 M
6. 5 pH

0. 5

0. 5

0. 5

0. 5

0. 5

0.1

0. 2

NE Std.
1 ug/ml

Neutral
Sample
Eluate

0.1

2. 5

2.5

2. 5

0.5 %
Zinc
Sulphate

. 05

. 05

. 05

. 05

.05

0.25 %
K3Fe(CN) 6

. 05

. 05

. 05

.05

.05

Hait Five
5N NaOH +
2% Ascorbic
Acid
.5
5N NaOH

~Hnutes

0.5

0. 5
.45

Wait Ten Minutes
2% Ascorbic
Acid

.05

0. 5

I
I
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Table #1 (continued)
Read samples within 30 minutes in a spectrophotofluorometer at 400/505 nM.
All units are ml.
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Table #1

The chemical scheme for the conversion of

norepinephrine to norepinephrinochrome and then to
norepinephrinolutine.

This conversion is specific

for norepinephrine (cf. text) and results in a fluorescent molecule that can be assayed quantitatively
in a spectrofluorometer.
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TABLE #2
Calculation of Endogenous NE and DA
Tissue Catecholamine Concentration (ug/g)
(Samp.FR. - T.Blk.FR.)
Std C
(Std.FR. - RB.FR.)
x
... one.

X

=

Vol .Samp.
Fct.Samp.

Where:
Std.FR.

=

RB.FR.

= Reagent blank fluorometric reading

Samp.FR.

=

T. Bl k. FR.

= Tissue blank fluorometric reading

Std.Conc.

=
=

Vol .Samp.

Standard fluorometric reading

Sample fluorometric reading

Standard concentration in ug.
The total volume of sample.

For the NE sample this

is the 6 mls. column eluate plus the K2co 3volume
used to neutralize it to 6.5 pH.

For DA this would

be the 1 ml. volume used to dissolve the freeze dried
column extract.
Fct.Samp.

= The fractional amount (in mls.) of the Vol .Samp. used
in the determination.

RF

= The recovery fraction as determined by the
11

recovery standards 11 for that particular run (ug

recovered/concentration added).
BPW

= The brain part weight in grams wet weight.

--

.I

I,
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steps.

First, (a) the 13 mllN HCl column elution volume

containing the dopamine was reduced in volume to concentrate the eluate.

The second procedure (b) used to

improve dopamine sensitivity was to develop a micro scheme
for fluorophore conversion.

Each will be discussed

separately.
(a) A freeze drying technique was employed to
reduce the 13 ml dopamine samples to dryness.

Dopamine was

found to be chemically stable throughout this process.
The freeze dryer was obtained from the Virtis Company
Model #10-010 and was equipped with a 150 liter/min vacuum
pump and a Mcleod gauge, so that an accurate measure of
internal vacuum could be determined.
Freeze drying was accomplished by the following
procedure.

The instrument was started and allowed to

equilibrate to a temperature of -65° centigrade and an
internal vacuum of 0.05 uM Hg.
was prepared.

An acetone-dry ice bath

Each dopamine sample eluate was placed in

a lOOml round bottom freeze-drying flask that had been
previously cleaned with concentrated potassium hydroxide
solution, and finally repeatedly rinsed with distilled
water.

Each sample was shell-frozen by gentle rotation

in the bath until solidly frozen.

Samples were placed

on the freeze dryer and the vacuum allowed to reequilibrate

76

to 0.05 uMHg. between sample placement.

This procedure

was repeated until all samples were frozen and placed on
the freeze dryer.

A maximum of 12 DA samples could be run

at any one time.
An additional freeze dryer recovery control was
Jl

added at this point of processing.

Since dopamine under-

went both exchange column chromatography separation and
freeze drying, a known standard was introduced prior to
freeze drying so that recovery could be monitored for
both operations.

To this end two standards were prepared

for each run (i.e., 2 standards with 10 samples) by adding
~

a known concentration of dopamine to 13 mls of 1 N HCl.
Freeze dried dopamine recovery was demonstrated both
fluorometrically and isotopically to be 90% + 5 down to
lOng.

It took 12 hours to reduce all samples to dryness.

The samples were removed from the freeze dryer and 1 ml
of 0.01 N HCl was added to each flask to redissolve the
crystalline dopamine.

One third of the HCl was placed in

a scintillation vial with 10 ml of HandiflourR.

The vial

was placed in a Packard Tri-Carb scintillation counter
and the radioactivity measured.

The remaining 0.66ml was

used for the OA fluorophore conversion.
(b) The dopamine fluorophore quantification method
was adapted from the trihydroxy indole method of Carlsson

li

L

r:
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and Waldeck (1958).

The method was modified to reduce

,I·l'.!
rlii

Il

the total reaction volume so that the concentration of the

1.1

"

dopamine fluorophore would be greater per unit volume.
During preliminary studies, it was determined that
the total reaction volume could be successfully reduced
from 6mls to 1.22 mls resulting in a 4.9 fold increase in
fluorophore concentration per unit volume.

The chemical

conversion scheme is shown in table #3.
After cooling the samples for one hour they were
poured into reading tubes and read in a spectrophotofluorometer at 330 nM excitation and 380 nM emission,
wavelengths uncorrected.

Spectral scans were plotted to

confirm the existence of uncontaminated dopamine in the
sample.

Calculation of

endogeno~s

dopamine was done using

the mathematical equation as shown in table #2.
In effect, freeze drying and the micro-volume
fluorophore conversion increased the method•s sensitivity
by 65 X.

It should be noted that accompanying this

increase in sensitivity was an accompanying increase in
tissue blank fluorescence.

To this end extreme care must

be taken in cleaning and rinsing all glassware used and
resin should be carefully cleaned by cycling to minimize
blank fluorescence.

Maximum final sensitivity of the

dopamine methods was determined to be lng.
I

I'
I·

~

78

TABLE #3
Conversion of Dopamine to Dopaminolutine
(Fluorometric Conversion)
Reagent

Standards
1X

Reagent
Blank

Sample

Blank

0.6

0.7

0.4

0.4

0.1

0.1

0.1

0.1

0. 3

0. 3

2X

4X

0.45

0.2

Citrate
Phosphate
Buffer

0.1

0.1

DA Std.
100 ng/ml

0.25

0. 5

DA Std.
1 ug/ml

0.1

Freeze
Dried
Sample
Na 2so 3

+

~aOR

0. 1

Boil Blank ONLY for Twenty Minutes
Iodided
Solution

0.02

0.02

0.02

0.02

0.02

0.02

Wait Five Minutes

0.1

0. 1

0. 1

0. 1

0. 1

Wait Five Minutes
5N Acetic
Acid

0.3

0. 3

0.3

0. 3

0. 3

0.3
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Table #3 (continued)

Boil for Thirty Minutes
Cool for Thirty Minutes (Read

All units are ml.

330/380nM)
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Table #3

The chemical scheme to convert dopamine to

dopaminochrome and on to dopaminolutine.

Dopaminolutine

is fluorescent and can be quantified with a spectrafluorometer.

This procedure is specific for dopamine

in that any possible norepinephrine contamination will
not affect the amount of fluorescence produced (cf. text).
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Calculation of the Isotopic Catecholamine Run Off Slope:
1) Determination of NE and DA disintegration per
minute (DPM) per gram of tissue (i.e., OPM/G): The amount
of 14 c NE and DA produced in vivo was determined by
measuring individually the NE and OA counts (CPM) per
sample as formulated in table #4.
2) Plotting and regression analysis of the isotopic data:

Eight turnover plots can then be generated

of 16 points each from the 128 (8 X 16) separate OPM/G
determinations.

Each plot is constructed separately.

First, the log DPM/G were determined (either natural or
common log may be used; however, if common log is used
a correction factor is necessary), and the corresponding
time coordinates converted to fractions of hours.

With

the abscissa as time in hours and the ordinate as log
DPM/G, each point can then be appropriately plotted.
sample plot is shown in figure #2.

A

Regression analysis

was performed on the isotopic data to determine the
slope (i.e., the run off slope or rate constant) and its
respective correlation coefficient (r).

The correlation

coefficient indicates the probability of fit of the data
points.

Only regression lines that demonstrated a

significant fit of p <.05 were used.

The regression lines

were then plotted and the slope determined.

The calculated
slope or run off slope is the rate at which the 14 c trans-
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TABLE #4
'

Calculation of the Isotopic Catecholamine Run Off Slope

'I~I

f

1

r

1
1

li

I'r''

DPM/G

=

(CPM-BG) X Vol. Samp.
BPM X CE X Fct. Samp. X Col. R.

:I

Where:
CPM

=

Counts per minute for each sample as counted in a
refrigerated Tri-Carb liquid scintillation
spectometer.

BG
Vol. Samp.

=
=

Background counts.
The total volume of sample.

For the NE sample this

is the 6ml column eluate before neutralization.
For DA this would be the lml volume used to dissolve
the freeze dried column extract.
BPW

= Brain part weight in grams (wet weight).

CE

= Counting efficiency as determined by a sealed
14 c OA and 14 c NE standard which was counted

simultaneously with each set of samples.
Fct. Samp.

= The fractional amount (in mls) of the Vol. Samp.
used for scintillation counting.
=

Col. R.

0.3mls, for NE Fct. Samp.

= Column recovery

=

For OA Fct. Samp.

l.Oml.

I','
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mitter is leaving the nerve terminal under study.

Once

both the endogenous level and the run off slope have
been determined, the turnover rate of 'NE and DA can be
calculated as their product (Brodie et al ., 1966).

Computer Calculation of Data:
Data handling initially presented itself as a
problem.

The large amount of data, for example for

control sets there were 320 samples and each sample had
16 data bits (i.e., volume, Fluorometer reading, etc.)

totalling over 5,000 numbers, had to be recorded and entered
into the appropriate phase of calculation.

Data recording

and repetitive calculations, however, lends itself readily
to computer adaptation.

To facilitate data handling a

computer based storage, calculation, and statistical
analysis system was developed.

The system was created

to be interactive (i.e., run from a computer based time
sharing terminal).

The computer language used was Pl-1.

All programs were designed to both store and output all
data entered and values calculated so that errors due
to manual handling of the data were eliminated.

All

programs were system tested for accuracy by at least two
different people on separate occasions.
All data was stored on a disk file system with
a back-up tape system to prevent loss of data in the event
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of a computer breakdown.

Statistical programs used in

this dissertation were adapted from existing documented
.II'

computer statistical systems.

Using the adapted programs,

determination of mean, standard deviation, standard error,
variance, range, maximum, minimum, t-test comparison,
plotting, regression analysis, and s)ope comparison by
covariance analysis could be carried out (Snedecor and
Cochran, 1967, pp. 421-425).
Monitoring Techniques: (cf appendix B for values)
It was necessary to insure "normal physiological
functionu (cf. below) in all experimental animals.

"Normal

physiological function" in these experiments is taken to
mean stable blood chemistries, core temperature, and blood
pressure throughout the experimental procedures.

All

experimental animals were equipped with an indwelling
arterial and venous femoral catheter.
the animals, these catheters

~ere

To avoid pain to

positioned through a

small incision, one half inch in length, following local
infiltration of 1% lidocaine (0.25 ml ).
One ml blood samples were drawn at regular
intervals for blood chemical analysis.

A model 165

Corning Blood gas analyzer was used to determine blood
pH, Pao , Paco 2 , HC0 3 , and bases of excess by standardized
2
procedures. An average of six arterial blood samples were
drawn per animal 20 minutes apart or as needed.

In the

il
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halothane experiments a 100 ul capillary tube was filled
with arterial blood and sealed immediately upon acquisition of the lml sample for subsequent determination of
blood halothane (cf. Lowe, 1964).
Blood pressure was monitored via the femoral
arterial cannula connected to a Hewlett Packard pressure
transducer and displayed on a recording polygraph.

II
I

"

Blood

pressure and heart rate were recorded just prior to each

I
'II!

blood sample.

II''

obtained.

Both systolic and diastolic pressures were

'I
II:

~
I
::i'

Where necessary mean blood pressure is con-

I

1\1

sidered to be l/3 X pulse pressure plus diastolic pressure

'~

"

where pulse pressure is equal to systolic pressure minus
diastolic pressure.

j

,,

Core body temperature was approximated by monitoring rectal temperature continuously with the aid of Yellow
Springs Telethermometer.

'I
'I

1

'

It was found that normal body

temperature (39°C) could be maintained easily in anesthetized animals by maintaining a 27°C room temperature.

'iii'!

An

auxiliary heating pad was seldom used.

Volatile and Gaseous Anesthetic Delivery
System for Halothane and Nitrous Oxide:
To deliver halothane, a volatile anesthetic, and
nitrous oxide (N 2o), a gaseous anesthetic, to the rabbits
under study, it was necessary to create an anesthetic
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delivery system to maintain consistent blood anesthetic
levels in animals from experiment to experiment.

Spon-

taneous breathing anesthesia delivery systems were disregarded.

A delivery system where ventilation and delivered

anesthetic concentration could be controlled minute to
minute was decided upon.
For this purpose, a semi-closed pediatric anesthetic circuit was chosen and modified to allow for
ventilation of two rabbits simultaneously.
distinct advantages of this system:

There are two

(1) continuous

control of physiologic blood gases and anesthetic concentration, (2) with a semi-closed system and a proper
evacuation system, there is no escape of the anesthetic
gases into the room to present a health hazard to
laboratory personnel (OSHA Standards).
The delivery system was comprised of five major
on line components (figure #3).

(a) An Ohio Medical

Metamatic veterinary ventilator was used to circulate
oxygen and anesthetic through the system and ventilate
the animals.

This ventilator is designed for anesthetic

gas delivery and allows for a wide variety of ventilation
patterns either volume or pressure limited.

(b) A series

of flow gauges and valves were used to regulate gas flow
and mixture.

A Foregger system was used.

(c) A halothane

vaporizer (Foregger Fluomatatic) which compensates for gas
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ANESTHESIA CIRCUIT

(c)

FIGURE # 3
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Figure #3

Diagram of the anesthesia circuit used in

conjunction with the nitrous oxide, halothane, and
halothane - nitrous oxide combination studies.

Shown:

(a) an Ohio Medical Metamatic Ventilator, (b) a series
of flow gauges, (c) a halothane vaporizer, (d) a carbon
dioxide absorber and (e) corrugated anesthetic tubing
equiped with two

11

0'ne way 11 valves.
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flow, ambient temperature, and barometric pressure to
deliver the precise concentration desired was used to
deliver halothane.

(d) A carbon dioxide (C0 2 ) soda lime
absorber was used to remove expired co 2 . Finally, (e)
disposable corrugated anesthetic tubing and two one way
valves were used to complete the circuit and maintain a

I
ill'

I,
I
'' .I

"one way" flow and screw clamps were interposed between
the animals and the circuit to adjust for difference in
animal compliance.

Tracheal Intubation:
Tracheal intubation in the rabbit is difficult
but can be accomplished consistently and nontraumatically
once the skill has been refined.

First the animals were

pre-oxygenated for 5 minutes with 100% o2 via an animal
mask. The ventilatory system was checked for leaks and
primed with 100% 0 2 during this period. A cuffed endotracheal tube of appropriate size was chosen. It was
found in this study that for every 1 kg of body weight,
1 mm in tube size was needed.

The endotracheal tube was

placed on an introducer so that the introducer protruded
l/2 inch past the end of the endotracheal tube.
was lubricated with lidocaine 2% jelly.

The tube

To aid endotrach-

eal intubation, pancuronium bromide, 0.126 ug/kg was
administered by lateral ear vein injection.

When the

I'
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animal was sufficiently paralyzed, laryngoscopy was performed and the vocal cords visualized.

The introducer

with the endotracheal tube in place was then inserted so
that the introducer could be seen to pass the vocal cords.
The introducer was then held in place and the endotracheal tube slowly inserted to a predetermined length.

The

endotracheal tube was then connected to the anesthetic
circuit and the cuff filled until no backflow around the
tube could be heard.

While the animal equilibriated

(approximately 10 minutes), a femoral cut down was performed as previously described.

Blood gases, blood

pressure, heart rate, and body temperature were monitored
and recorded.

Ventilator rate and/or tidal volume was

adjusted if necessary to maintain PC0 2 at 35-40 torr.
When all recorded paramters were determined to be normal
the experimental procedure was begun.

If for any reason

"normal physiological function" was not established, the
animal was eliminated and a repeat experiment performed.
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Drug Scheduling
Three anesthetic agents were studied:
halothane and nitrous oxide.

ketamine,

These three agents have

different clinical uses within the field of anesthesia.
Each anesthetic was chosen for its dissimilarities from
the other two so that, hopefully, different actions on
central adrenergic neuronal transmitters could be demonstrated.

Ketamine:
Ketamine, a short acting

11

dissociative 11 anesthetic,

is characterized by both analgesia and narcosis.

It was

used at a dose of 40mg/kg which corresponds well with the
reported ketamine doses for rabbits in the literature
(Sung et al., 1973; Biggio et al., 1974).
dose used in humans is 2.0 - 8.0 mg/kg.

The ketamine
Interestingly, a

scan of the literature indicates that the lower an animal
is on the evolutionary scale, the larger the ketamine
dose needed for anesthesia.

It appears that the dose

needed for ketamine anesthesia is inversely related to

:1

phylogeny (Doubrava and Larson, 1971 ).

li
1!1

In this study, ketamine was given to 20 rabbits
all weighing between 2.5 and 3.5 kg by lateral ear injec-

'I

II
II
;!II'

,.I

,l.lj

tion.

Preliminary studies showed that cardiovascular

depression occurred if ketamine was injected at a concen-

II
!

I
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tration of 100 mglml.

The injection concentration

decided upon for experimentation was 50 mglml.

The

ketamine infusion rate \'las held constant at 1.0 mllmin.
At this concentration and infusion rate, no respiratory
or cardiovascular depression was noted.

A control sub-

group was administered saline in place of ketamine.
All ketamine experiments were begun between 9:00
and 10:00 a.m.

Four animals, one for each of the four

time points (40, 55, 90, and 105 min.) were handled
simultaneously.

Each animal was prepared with an intra-

ventricular injection site as previously described,
allowed 1.5 hours recovery, then injected with the 14 c-Ltyrosine using the schedule shown below.
D

c

I

I

I

I

I

I

I

I

0

15

30

45

60

75

90

105

A

B

~;li

k i 11

K

nutes

Where:
A i s the 14 c-tyrosine injection time point for 40 min.
14 c-tyrosine injection time point for 55 min.
B is the
c is the 14 c-tyrosine injection time point for 90 min.
14 c-tyrosine injection time point for 105 min.
D i s the
K is the ketamine injection time point.
,,

:;

The thirty minute time period was used for ketamine because this is the normal anesthetic time expected

II
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for this agent at this dose.

Each animal was monitored

for body temperature and heart rate.

Blood gases were

drawn as previously described (cf. appendix A for monitoring values).

Animals were sacrificed by decapitation.

Tissue dissection, extraction, fluorometric and isotopic
procedures were carried out as discussed in the previous
sections.

Catecholamine data obtained from the sham

injected control animals was not found to differ from the
awake control group.

Ketamine Turnover:
In this study ketamine anesthesia was produced
using the single intravenous injection technique.

To

measure ketamine turnover using this technique, it is
necessary to correct the isotopic data such that it
reflects ketamine's action over the entire turnover time
course, 0 - 105 minutes, rather than the actual 30 minute
ketamine anesthesia time.

To accomplish this correction

the formula shown below was applied to each of the
ketamine data points.

The correction was achieved by

applying the formula:

(control DPM - ketamine DPM)
ketamine fractional time
where the ketamine fractional time for the 40 minute
point equals 0.75; for the 55 minute point, 0.545; for
the 90 minute point, 0.33; and for the 105 minute point,
0.285.

The fractional times were derived by dividing the
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30 minute ketamine anesthesia time by the total time for
· d , e.g., 30 min. = 0.75 for the 40 minute time
eac h per1o
40 min.
period. Using this corrected isotopic data, ketamine
turnover was calculated according to the formula shown in
the section Turnover Calculations.

Halothane:
Halothane is one of the most widely ·used inhalation anesthetics today.

It is a halogenated, volatile

liquid at room temperature and requires a vaporizer for
controlled use.

Halothane produces profound narcosis

but unlike ketamine results in little, ifa-~nalgesia
at clinical concentrations.

Some degree of muscle relaxa-

tion is common.
All animals were prepared as previously described.
Each was intubated and ventilated.
handled simultaneously.

Two animals were

Halothane was added into the

anesthetic circuit using a Foregger Fluomatic vaporizer.
Two percent halothane was used continuously.

When the

depth of anesthesia was established, femoral, arterial
and venous catheters were implanted.
allowed to stabilize.

The animals were

Blood gases were determined and

modifications of the respiratory rate or tidal volume
were made if needed according to PC0 2 values. Each animal
was maintained on 2% halothane for a 3 hour period. The
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isotopic injection was adjusted so that each isotope time
period ended simultaneously with the anesthesia period as
sho\'tn below.
Start
Halothane

0

0

c

B

kill

A

120

60

180

t~inutes

Where:
A is the 14 c-tyrosine injection time point for 40 min.
B is the 14 c-tyrosine injection time point for 55 min.

c is the 14 c-tyrosine injection time point for 90 min.
.
0 is the 14c - t yros1ne
injection time point for 105 min.
Blood halothane levels were determined to insure
a consistent blood halothane on each animal and between
animals.

This level was 12.3 mg% ± 0.85.

It should be

noted that the halothane vaporizer used was rated for a
minimum flow of 4 liters/minute.
geared to human use.

This flow rate is

The considerable excess of gas

necessarily input into the system was vented through
an exhausted pressure sensitive pop-off valve.
A halothane recovery study was also performed.
Sixteen animals were used.
2%

halot~ne

.

Each group was treated with

in precisely the same manner as described

·~

before except these animals were allowed to recover for a
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two hour period (cf. below).

HR

H

I 13hb'
3 h Grs

I

D

I

2 hb6rs 10

c
I
15

A

B

I
30

I
45

I
75

I
60

I
90

k i 11
I
10 5

~·1inutes

J;
1111
11

1

1

1:
1.:1

1

~1111

VJhere:
A is the 14 c-tyrosine injection time point for 40 min.

14c -tyros1ne
.
B is the
injection time point for 55 min.

c is the
D i s the

14
14

C-tyrosine injection time point for 90 min.
C-tyrosine injection time point for 105 min.

H is the 3 hour halothane period.
HR is the 2 hour halothane recovery period.
During the two hour period, the animals were maintained
in a 100% oxygen environment.

Although continuous blood

pressure monitoring was impossible due to animal movement,
blood pressure measurements and blood gas determinations
were intermittently made throughout the recovery period
to insure

11

normal physiologic parameters.

11

Blood samples

were taken prior to sacrifice to determine the blood
halothane level two hours post anesthesia.

Turnover cal-

culation for both the halothane and the halothane recovery
data was done as shown in the Turnover Calculation section.
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Nitrous Oxide Studies:
Nitrous oxide (N o), a gas at standard temperature
2
and pressure, is supplied in a compressed gas cylinder
and was connected to the anesthesia flow valve assembly
by appropriate plumbing.

This gas is clinically used to

produce profound analgesia.

In addition, its use in

balanced anesthesia decreases the concentration of halogenated anesthetic needed.

Deep narcosis or muscle

relaxation is not seen at concentrations below 80%.
For these studies, a 2 liter flow of nitrous
oxide mixed with a 3 liter oxygen flow was used.

In

this way, a 40% nitrous oxide concentration was delivered
into the anesthesia circuit.
Animals were prepared as previously described.
With the aid of pancuronium bromide, intubation was
performed and the animals equilibrated on the 40% nitrous
oxide and 0 2 gas mixture. The femoral cut down was performed and venous and arterial lines implanted. Gas
samples were drawn after a 10 minute equilibration period
and ventilatory parameters were adjusted if needed.

Any

animals which did not demonstrate "normal physiological
function" were eliminated and repeat experiments performed.
The intraventricular injection site was prepared
as described earlier.

tore~(

I

Physiologic parameters were monithe predetermined intervals. 14 c-tyrosine

1.
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injections were made at 40, 55, 90 and 105 minutes prior

to the 3 hours nitrous oxide termination point.

The time

sequence is shown below.
Start

NlO

I

I

D

;

B

A

I

K;ll

~o------~------~6~0------~----~1~2~0------~------~180
r~

I

i nut e s

II,'
.j;l'
Ji

Where:
A is the 14 c-tyrosine injection time point for 40 minutes.
B is the 14 c-tyrosine injection time point for 55 minutes.

.
c is the 14c - t yros1ne
injection time point far 90 minutes.
.
injection time point far 105 minutes.
D is the 14,.. . - t yros1ne
Two animals were ventilated simultaneously on the
anesthesia circuit.

It was found necessary to run two

animals each day on two consecutive days.
processing was handled simultaneously.

The remaining

All phases of the

nitrous oxide experimentation were identical to that
described for halothane except for the drug delivered.
Once sacrificed, all animal tissues and data calculations
were treated as previously described.

Halothane and Nitrous Oxide:
In this study halothane and nitrous oxide were
used in combination.

This halothane-nitrous oxide combi-

nation is widely used as a basal anesthesia resulting in

I',:1•.
1:'

.,
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excellent narcosis and muscle relaxation and profound
analgesia.
Animals were handled as before.

Induction and

intubation were facilitated with the use of pancuronium
bromide.

Animals were ventilated on halothane (2%) and

nitrous oxide (40%) in combination.

Femoral arterial

and venous lines were implanted and the animals allowed
to equilibrate.

Blood gases were monitored and ventila-

tory parameters adjusted if necessary.

The three hour

drug and turnover schedule used was a previously described
in both halothane and nitrous oxide sections.

CHAPTER III
RESULTS
Introduction:
This study investigated the effects of ketamine,
halothane, nitrous oxide and halothane-nitrous oxide in
combination on dopamine and norepinephrine turnover and
their endogenous levels to determine if these anesthetic
agents have common and/or unique effects specific to any
or all of the brain regions studied.

The four brain

areas considered were the mesencephalon, thalamus,
hypothalamus and cortex.
Dopamine and norepinephrine turnover and related
values are shown in tabular form for the awake (unanesthetized) control and experimental groups in tables 5,
6, 8, 9, 11, 12, 14 and 15.

These values include:

(a) the endogenous content in ug/g, (b) the rate
constant, which is the rate of isotopic amine disappearance as described by the first derivative of the
natural log function, (c) the turnover time, which is
the mean length of time necessary for one molecule to
turnover and is calculated as the reciprocal of the
rate constant, and (d) the turnover value itself, which

100
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expresses the amount of amine in nanograms which is
degraded per hour.

Awake (unanesthetized) control

endogenous and turnover levels for norepinephrine and
dopamine determined in this study are consistent with
published endogenous and turnover values (Glisson et
al., 1972; Brodie et al ., 1966; Costa and Neff, 1970).
Two comparisons are important in this study.
First, values for each anesthetic agent have been
compared to values obtained from awake unanesthetized
animals to determine alterations from normal amine
metabolism as a result of the anesthetic agent.

Second,

the effects of each anesthetic agent were compared with
these and the other anesthetic agents to determine likeness and dissimilarities between them.

]i

102
Mesencephalon

Turnover and Endogenous Level as
Compared to Awake Control:

~

The mean endogenous dopamine level in the

i'l!

mesencephalon (table #5) for the awake control was found

I!

to be 0.333 ug/gram of tissue.

l

Ketamine and nitrous

I•

I,

oxide administration each resulted in a drop in dopamine
from control levels.

i·

With ketamine a 55% decrease

{p<O.Ol) in endogenous dopamine occurred, while nitrous
oxide had only a slight reducing effect (2%) (cf. table
#5 and figure #4).

Halothane and halothane in combina-

tion with nitrous oxide resulted in a significant
increase in endogenous dopamine compared to awake
control.

The halothane group induced a 51% increase

{p<0.05) in DA levels and halothane plus nitrous oxide
in combination resulted in a 203% increase in endogenous
dopamine {p<O.Ol) (figure #4).
The endogenous norepinephrine awake control
level in mesencephalon was found to be 0.323 ug/gram
(table #6).

As in the case of dopamine, a decrease in

endogenous norepinephrine content occurred with ketamine
and nitrous oxide.

Ketamine resulted in a 56% decrease

(p<.Ol) and nitrous oxide caused an 11% decrease in
norepinephrine (figure #4).

Halothane alone and in
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TURNOVER
. TIME

TURNOVER
ng/g/hr

AWAKE CONTROL

0.333±,15

1.190

0.840

396

KETAMINE ANESTHESIA

0.151±,05

0.747

1.339

248

HALOTHANE ANESTHESIA

0.503±,08

1.520

0.657

506

NITROUS OXIDE ANESTHESIA

0.326±,04

1.LHO

0.709

470

HALOTHANE PLUS
NITROUS OXIDE ANESTHESIA

1.010±,13

1.440

0.627

1450 .
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Table #5

Effects of ketamine (40 mg/kg) halothane (2%),

nitrous oxide (40% in oxygen), and the combination of
halothane (2%) plus nitrous oxide (40%) on mesencephalic
dopamine.

Endogenous content is expressed as the mean

~

the standard deviation, the rate constant is the rate of
disappearance of isotopic dopamine over time (also called
the run off slope), turnover time is shown in fractions
of hours, and turnover rate is expressed in nanograms per
gram of brain (wet weight) per hour.

The number of

animals in the control group was 52; in each experimental
group 16 animals were used.
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Figure #4

Endogenous dopamine and norepinephrine effects

in the mesencephalon graphed as a percent of awake control.
Plots are shown for ketamine (40mg/kg), halothane (2%),
nitrous oxide (40% in oxygen), and the

combination~of

halothane (2%) plus nitrous oxide (40%).

Statistical

testing was accomplished by Student•s T test and significance indicated in terms of probability (p).
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ENDOGENOUS
RATE
ug/gram
CONSTANT

TURNOVER
ng/g/hr

. A\"/AKE CONTROL

0.323±,08

0.929

1.076

300

KETAMINE ANESTHESIA

0.143±,06

0.625

1.625

202

HALOTHANE ANESTHESIA
NITROUS .OXIDE ANESTHESIA

0.467± .04
0.289± .04

1.074
0.730

0.931
1.370

347
236

HALOTHANE PLUS
NITROUS OXIDE ANESTHESIA

0.370± .06

0.806

1.240

260
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TIME
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Table #6

Norepinephrine effects by ketamine (40 mg/kg),

halothane (2%), nitrous oxide (40% in oxygen), and the
combination of halothane (2%) plus nitrous oxide (40%)
in the mesencephalon.
as the mean

±

Endogenous content is expressed

the standard deviation, the rate constant

is the rate of disappearance of isotopic norepinephrine
over time (ie. run off slope), turnover time is shown in
fractions of hours, while turnover rate is expressed in
nanograms per gram of brain (wet weight) per hour.
The number of animals in

~he

control group was 52; in

each experimental group 16 animals were used.

I'
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combination with nitrous oxide resulted in a 45% (p<O.Ol)
and 28% increase, respectively, in endogenous norepinephrine levels over control (figure #4).
Control dopamine turnover in the mesencephalon
(table #5) was found to be 396 ng/g/hr.

Ketamine

reduced dopamine turnover significantly 37% (p<O.Ol ).
Halothane, nitrous oxide, and halothane-nitrous oxide
in combination increased dopamine turnover.

For either

agent alone the effects were not as dramatic as when
combined.

Halothane alone resulted in a 28% increase

and nitrous oxide alone resulted in a 19% increase in
turnover.

When used in combination the resulting

increase was a significant (p<O.Ol) 266% increase (cf.
table #5 and figure #5).
Norepinephrine turnover in the mesencephalon
differed in pattern from that of dopamine.

Halothane

was the only agent that caused an increase in norepinephrine turnover (15%).

Ketamine, nitrous oxide,

halothane-nitrous oxide in combination all resulted in
a decrease in norepinephrine turnover.

Nitrous oxide

resulted in a 21% decrease, halothane in combination
with nitrous oxide resulted in a 13% decrease in turnover and ketamine caused a 33% decrease which was significant, p<O.Ol (cf. figure #5).
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Figure #5

Anesthetic effects on mesencephalic dopamine

and norepinephrine graphed as a percent of awake control.
Data is shown for ketamine (40 mg/kg), halothane (2%),
nitrous oxide (40% in oxygen) and the combination of
halothane (2%) plus nitrous oxide (40%).

Statistical

comparisons to awake control were made by covariance
analysis and are reported in terms of probability (p).
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Summary of mesencephalic data:
1) Ketamine caused significant decreases in
endogenous dopamine and norepinephrine
content and turnover.
2) Halothane produced in a significant increase
in endogenous dopamine and norepinephrine

i

levels.
3) The combination of halothane plus nitrous
oxide resulted in a significant increase in
endogenous and turnover levels.

Comparison of Turnover and Endogenous
Levels Between Anesthetics:
The second important goal encompassed by this
dissertation is to compare the NE and DA data of each
anesthetic agent to the data of all other anesthetic
agents.

This comparison will indicate the similarities

and dissimilarities in change of amine metabolism
between individual anesthetics.
When ketamine, halothane, nitrous oxide, and
halothane plus nitrous oxide groups were compared to one
another, all norepinephrine endogenous and turnover
level comparisons were significantly different with one
exception.

Halothane vs. halothane plus nitrous oxide

endogenous levels when tested were not significantly
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different (table #7).

In the case of dopamine for these

same group comparisons, all endogenous levels were
significantly different, however, only ketamine vs.
halothane, nitrous oxide, and halothane plus nitrous
oxide in combination resulted in significant differences
for the dopamine turnover data (table #7).
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ME S E NC E P HAL 0 N
ANESTHETIC GROUP

DOPAMINE
Endogenous Turnover

NOREPINEPHRINE
Endogenous Turnover

KET

VS

HAL

P<0.01

P<0.01

P<0.01

P<0.01

KET

vs

p <0. 01

P<0.01

p <0. 01

P<0.01

KET

vs

N20
HAL + N20

p <0. 01

p <0. 01

p <0. 01

P<0.01

HAL

vs

N2o

p <0. 01

NS

p <0. 01

P<O.Ol

HAL

vs

HAL + N20

p <0. 01

NS

NS

P<O.Ol

N2o vs

IIAL + N20

p

<0. 01

NS

p <0. 01

----KET = Ketamine

HAL

= Halothane

p <0.

01

I

N20 = Nitrous Oxide

TABLE #7
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Table #7

Statistical cross comparisons of endogenous

levels (Student's T test used) and turnover rates
(covariance analysis was used) for dopamine and norepinephrine in the mesencephalon.

Significance is indicated

in terms of probability (p); insignificant cross comparisons are indicated by NS.

Cross comparisons for the

anesthetic groups ketamine (40mg/kg), halothane (2%),
nitrous oxide (40%), and the halothane-nitrous oxide
combination are shown.
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Thalamus

Turnover and Endogenous Levels as
Compared to Awake Control:
Control dopamine turnover in the thalamus was
found to be 422 ng/g/hr (table #8).

Ketamine and

nitrous oxide cause dopamine turnover to slow to 361
ng/g/hr and 388 ng/g/hr, respectively.

This 14% and

8% drop in dopamine turnover was not significant
(figure #6).

Halothane alone resulted in an increase

in dopamine turnover to 517 ng/g/hr (23%; p<O.Ol).
When halothane-nitrous oxide combination was used, no
significant effects were found, seemingly a cancellation
of halothane's increase with nitrous oxide's decrease.
Noradrenergic turnover was affected to a greater
extent than was the dopamine turnover.

Control nore-

pinephrine turnover was found to be 146 ng/g/hr (table
#9).

Ketamine had the least effect on thalamic turnover.

Turnover accelerated from 146 ng/g/hr to 156 ng/g/hr
or 7% (figure #6).

Both halothane and nitrous oxide

caused large increases in norepinephrine turnover in
this brain area.

Nitrous oxide resulted in a 28%

increase, while halothane caused a 154% rise in turnover
(i.e., 146 ng/g/hr to 371 ng/g/hr; table #9).

When

these agents were used in combination, proportionately
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D 0 P A MI NE
T HA L.A MUS
ENDOGENOUS
RATE
ug/gram
CONSTANT

TURNOVER
TIME

TURNOVER
ng/g/hr

AWAKE CONTROL

0.380±,16

1.110

0.900

422

KETAMINE ANESTHESIA

0.238±.04

0.951

1.051

361

HALOTHANE ANESTHESIA

0.364± .06

NITROUS OXIDE ANESTHESIA

0.286±,04

1.360
1.020

0.735
0.980

517
388

HALOTHANE PLUS
NITROUS OXIDE ANESTHESIA

1.092±,13

1.180

0.847

448
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Table #8

Effects of ketamine (40 mg/kg), halothane

(2%), nitrous oxide (40%) and the combination of
halothane-nitrous oxide on thalamic dopamine.

Endogenous

content is expressed as the mean ± the standard deviation,
the rate constant is the rate of disappearance of
14 c-dopamine over time (i.e., run off slope), turnover
time is shown in fractions of hours and turnover rate is
expressed in nanograms per gram of brain (wet weight) per
hour.

The number of animals in the control group was 52;

in each experimental group 16 animals were used.
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Figure #6

Anesthetic effects on thalamic dopamine and

norepinephrine turnover graphed as a percent of awake
control.

Data is shown for ketamine (40 mg/kg), halo-

thane (2%), nitrous oxide (40% in oxygen}, and the
combination of halothane (2%) plus nitrous oxide (40%).
Statistical comparisons to awake control were made by
covariance analysis and are indicated in terms of
probability (p).
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Table #9

Norepinephrine effects by ketamine (40 mg/kg),

halothane (2%), nitrous oxide (40%) and the combination of
halothane- nitrous oxide in the thalamus.

Endogenous

content is expressed as the mean ± the standard deviation,
the rate constant is the rate of disappearance of 14cnorepinephrine over time (ie. run off slope), turnover
time is shown in fractions of hours, while turnover rate
is expressed in nanograms per gram of brain (wet weight)
per hour.

The number of animals in the control group·

was 52; in each experimental group 16 animals were used.
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a larger than additive increase in norepinephrine turn-

over resulted.

The resultant increase was to 761 ng/g/

hr or a highly significant 421% increase over control
(figure #6).
For the awake control, thalamic endogenous
dopamine was found to be 0.380 ug/gram of tissue (table
#8).

Administration of ketamine caused endogenous

dopamine levels to decrease from 0.380 to 0.238 ug/gram
or 37% (table #8 and figure #7).
be significant.

This did not prove to

Halothane and nitrous oxide separately

also had no significant effect on dopamine endogenous
levels.

However, when in combination, halothane and

nitrous oxide resulted in a dramatic rise in endogenous
dopamine.

The level rose from 0.380 ug/g control to

1.092 ug/g, a 187% increase (cf. table #8 and figure #7).
This finding is strikingly similar to that found in the
mesencephalon.
Endogenous norepinephrine levels in the thalamus
were found to be 0.377 ug/g.

Halothane anesthesia

resulted in a 22% rise in norepinephrine (table #9,
figure #7).

Nitrous oxide, on the other hand, caused

an 18% fall in the amine content.

These two anesthetic

agents, when combined, seemed to be additive resulting
in a net cancellation of the individual effects.

The

endogenous norepinephrine level with the halothane and
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Figure #7

Effects on endogenous dopamine and norepine-

phrine in the thalamus graphed as a percent of awake
control.

Plots are shown for ketamine (40 mg/kg), hal-

othane (2%), nitrous oxide (40%) and the combination of
halothane (2%) plus nitrous oxide (40%).

Statistical

testing was accomplished by Student•s T test and significance indicated in terms of probability (p).
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nitrous oxide combination was 0.370 ug/g which was a 2%

change from control (cf. table #9 and figure #7).

In

the case of ketamine, a 51% (p<O.Ol) decrease in norepinephrine from control occurred.
Summary of thalamic data:
1) Halothane increased norepinephrine and
dopamine turnover.
2) Halothane plus nitrous oxide increased norepinephrine turnover and increased dopamine
endogenous levels.
3) Ketamine decreased endogenous norepinrphrine
levels.

Comparison of Turnover and Endogenous
Levels Between Anesthetics:
When the groups ketamine, halothane, nitrous
oxide, and halothane-nitrous oxide were compared to one
another to examine their likeness and dissimilarities it
was found that all comparisons were significantly different in the case of both dopamine and norepinephrine
endogenous data.

Only two group comparisons, ketamine

vs. halothane and halothane vs. nitrous oxide, were
found to be significantly different for the dopamine
turnover.

For norepinephrine turnover, all groups were

again significant except for ketamine vs. nitrous oxide

~

_j
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(table #10).
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THALAMUS
ANESTHETIC GROUP

DOPAMINE
Endogenous Turnover

KET

vs

HAL

p <0. 01

p <0. 01

p <0. 01

p <0. 01

KET

vs

p <0. 0 5

NS

p <0. 01

NS

KET

vs

N20
HAL + N20

p <0. 01

NS

p <0. 01

p <0. 01

HAL

vs

p <0. 0 5

p <0. 05

p <0. 01

p <O. 01

HAL

vs

N2o
HAL + N20

p <0. 01

NS

p <0. 01

p <0. 01

N20

vs

HAL + N20

p <0. 01

NS

p <0. 0 5

p <0. 01

KET
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= Ketamine

HAL

= Halothane
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Table #10

Statistical cross comparisons of endogenous

levels (Student's T test was used) and turnover rates
(covariance analysis was used) for dopamine and norepinephrine in the thalamus.

Significance is indicated in

terms of probability (p); insignificant cross comparisons
are indicated by NS.

Cross comparisons for the anes-

thetic groups ketamine (40 mg/kg), halothane (2%), nitrous
oxide (40%) and halothane-nitrous oxide are shown.
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Hypothalamus

Turnover and Endogenous Levels as
Compared to Awake Control:
In the hypothalamus the majority of the changes
seen in catecholamine metabolism as a result of the
anesthetic agents tested were found to be dopaminergic.
Control dopamine turnover in the hypothalamus, shown in
table #11, was 535 ng/g/hr.

Ketamine, halothane,

nitrous oxide, and halothane-nitrous oxide in combination resulted in a significant increase over the control
level.

Ketamine and nitrous oxide raised hypothalamic

dopamine turnover 39% and 32% {p<O.Ol) respectively (cf.
figure #8).

Halothane and halothane-nitrous oxide

resulted in larger increases in dopamine turnover, 89%
(p<O.Ol) for halothane alone and 162% {p<O.Ol) for
halothane in combination with nitrous oxide (cf.

figu~e

#8).
Relative to dopamine, norepinephrine turnover
(shown in table #12) was essentially unaffected in the
hypothalamus by each of the anesthetic agents.

Awake

control norepinephrine turnover was found to be 889 ng/
g/hr.

Ketamine anesthesia resulted in a 30% drop in

norepinephrine turnover while halothane and nitrous
oxide caused a 32% and 31% decrease respectively when
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RATE
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TIME

TURNOVER
ng/g/hr

AWAKE CONTROL

0.601±.19

0.890

1.124

535

KETAMINE ANESTHESIA
HALOTHANE ANESTHESIA

0.309±.06
1.154± .19

1.236
1.648

0.809
0.607

743
1012

NITROUS OXIDE ANESTHESIA

0.828±.13
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0.851
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Table #11

Effects of ketamine (40 mg/kg), halothane (2%),

nitrous oxide (40%) and the combination of halothanenitrous oxide on hypothalamic dopamine.

Endogenous

content is expressed as the mean ± the standard deviation,
the rate constant is the rate of disappearance of 14cdopamine over time (i.e., run off slope), turnover rate
is expressed in nanograms per gram of brain (wet weight)
per hour.

The number of animals in the control group was

52; in each experimental group 16 animals were used.
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Figure #8

Hypothalamic effects on dopamine and norepin-

ephrine turnover expressed as a percent of awake control.
Data is shown for ketamine (40 mg/kg}, halothane (2%),
nitrous oxide (40%) and the combination
plus nitrous oxide (40%).

o~halothane

(2%)

Statistical comparisons to

awake control were made by covariance analysis and are
indicated in terms of probability (p}.
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Table #12

Effects on norepinephrine by ketamine (40 mg/

kg), halothane (2%), nitrous oxide (40%) and the combination of halothane (2%) plus nitrous oxide (40%) in the
hypothalamus.
±

Endogenous content is expressed as the mean

the standard deviation, the rate constant is the rate of

disappearance of the 14c-norapinephrine over time (ie. the
run off slope), turnover time is shown in fractions of
hours, and turnover rate is expressed in nanograms per
gram of brain (wet weight) per hour.
mals in the control group was 52;
group 16 animals were used.

The number of ani-

in each experimental
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compared to awake control.

Halothane when used in

conjunction with nitrous oxide had little effect.

A

5% drop in NE turnover was seen (cf. figure #8).
The mean control endogenous dopamine level in
the hypothalamus was found to be 0.601 ug/g of tissue
(table #11).

Ketamine, the only treatment group to

lower endogenous dopamine levels, resulted in a mean
value of 0.309 ug/g or a 49% decrease (figure #9).
Halothane and nitrous oxide alone and in combination
resulted in dramatic increases in endogenous dopamine
levels.

A 92% {p<0.05) increase (0.601 ug/g to 1.154

ug/g; table #11) occurred with halothane anesthesia
(figure #9).

Nitrous oxide increased dopamine levels

38% over control.
areas.

This effect is seen in other brain

Nitrous oxide in combination with halothane

significantly increased endogenous dopamine levels to
2.07 ug/g (table #11) or a 245% increase over control
(cf. figure #9).
Norepinephrine endogenous levels in the hypothalamus were generally unaffected by the anesthetic
agents tested.

Ketamine, the only anesthetic to have

significant effect upon endogenous norepinephrine levels
resulted in a 64% drop from control (0.823 ug/g to 0.293
ug/g; cf. table #12 and figure #9).

In the case of

halothane a nonsignificant 11% increase in endogenous
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Figure #9

Effects on endogenous dopamine and norepine-

phrine in the hypothalamus graphed as a percent of awake
control.

Plots are shown for ketamine (40 mg/kg), hal-

othane (2%), nitrous oxide (40%) and the combination
halothane - nitrous oxide.

Statistical testing was

accomplished by Student•s T test and significance indicated in terms of probability (p).
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norepinephrine levels resulted (see table #12 and figure
#9) while with nitrous oxide a 20% decrease was found.
When the two agents were used in combination the effect
resultant was a nonsignificant 10% drop in endogenous
norepinephrine levels.
Summary of hypothalamic data:
1) Ketamine resulted in a significant decrease
in both dopamine and norepinephrine endogenouse levels.

Dopamine turnover was signifi-

cantly increased.
2) Halothane significantly increased both
turnover and endogenous dopamine levels.
3) Nitrous oxide increased dopamine turnover
and endogenous levels.
4) The combination of halothane-nitrous oxide
resulted in increased turnover and endogenous
dopamine levels.

Comparison of Turnover and Endogenous
Levels Between Anesthetics:
When the groups ketamine, halothane, nitrous
oxide, and halothane-nitrous oxide were compared to one
another to examine their likenesses and dissimilarities,
it was found that for both dopamine and norepinephrine
all endogenous level comparisons were found to be
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significantly different from one another except for
nitrous oxide vs. halothane-nitrous oxide, norepinephrine
only.

For dopamine turnover all comparisons were signi-

ficant except for ketamine vs. nitrous oxide.

For

norepinephrine turnover distinct alterations of metabolism appeared only for the halothane-nitrous oxide
group when compared to either halothane or nitrous
oxide (cf. table #13).
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HYP 0 T HAL AMUS
ANESTHETIC GROUP

DOPAMINE
Endogenous Turnover

NOREPINEPHRINE
Endogenous Turnover

KET

vs

HAL

P<0.01

P<0.01

P<0.01

NS

KET

vs

P<0.01

NS

P<0.01

NS

KET

vs

N20 ...
HAL + N20

P<0.01

P<0.01

P<0.01

NS

HAL

vs

HAL
N2o

P<0.01

P<0.01

P<0.01

NS

vs

N20
HAL + N20

p <O. 01

P<o. o 1

P<0.01

P<0.05

vs

HAL + N20

p <0. 01

P<0.01

NS

P<0.05

'

KET

= Ketamine

HAL

= Halothane

N20

= Nitrous Oxide

T AB L E # 13
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Table #13

Statistical cross comparison of endogenous

levels (Student's T test was used) and turnover rates
(covariance analysis was used) for dopamine and norepinephrine in the hypothalamus.

Significance is indicated in

terms of probability (p); insigifnicant cross comparisons
are indicated by NS.

Cross comparisons for the anesthetic

groups ketamine (40 mg/kg), halothane (2%), nitrous oxide
(40%) and the combination of halothane (2%) plus nitrous
oxide (40%) in combination are shown.
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Cortex

Turnover and Endogenous Levels as
Compared to Awake Control:
Control dopaminergic turnover in the cortex was
found to be 112 ng/g/hr (table #14).

Ketamine, which

caused a decrease in dopamine turnover in the mesencephalon and thalamus, also caused a decrease in the
cortex.

Dopamine turnover in the ketamine group was

found to be 72 ng/g/hr, which is a significant 36%
decrease (cf. table #14 and Figure #10).
also decreased dopamine turnover.
112 ng/g/hr was seen.

Halothane

A dramatic drop from

This was a significant 76% drop

as is shown in figure #10.

Nitrous oxide had little

effect on dopamine turnover, however, in combination
with halothane, dopamine turnover increased to 258 ng/
g/hr, a marked 111% increase over control (cf. figure
#10 and table #14).
Dramatic changes were seen in cortical norepinephrine turnover by all anesthetics.

Awake control

norepinephrine turnover shown in table #13 was 80 ng/g/
hr.

Ketamine, halothane, nitrous oxide, and halothane-

nitrous oxide (seen in figure #10) resulted in increased
turnover levels from awake control.
120% increase to 175 ng/g/hr.

Ketamine caused a

Halothane and nitrous

l

l.(')

o::;j.-i

D0 P A MI NE
CORTEX
ENDOGENOUS
RATE
ug/gram
CONSTANT

TURNOVER
TIME

TURNOVER
ng/g/hr

KETAMINE. ANESTHESIA

0.105±,10
0.079±.04

1.070
0.689

0.935
1.451

112
72

HALOTHANE ANESTHESIA

0.184± 03

3.860

27

NITROUS OXIDE ANESTHESIA

0.133±,02

0.259
1.030 .

0.971

108

HALOTHANE PLUS
NITROUS OXIDE ANESTHESIA

0.362± .04

0.712

1.404

258

AWAKE CONTROL

I

T A BL E # 14
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Table #14

Effect of ketamine (40 mg/kg), halothane (2%),

nitrous oxide (40%), and the combination of halothanenitrous oxide on cortical dopamine.

Endogenous content

is expressed as the mean ± the standard deviation, the
rate constant is the rate of disappearance of 14 C-dopamine
over time (i.e., the run off slope), turnover rate is
expressed in nanograms per gram of brain (wet weight) per
hour.

The number of animals in the control group was 52;

in each experimental group 16 animals were used.
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P<0.05
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Figure #10

Cortical effects on dopamine and norepine-

phrine turnover expressed as a percent of awake control.
Bar graphs are shown for ketamine (40 mg/kg), halothane
(2%), nitrous oxide (40%) and the combination halothanenitrous oxide. Statistical comparisons to awake control
were made by covariance analysis and are indicated in
terms of probability (p).
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oxide increased norepinephrine turnover 122% and a 145%,
respectively (cf. table #15 and figure #10).

When

nitrous oxide and halothane were used in combination,
turnover increased 300% (p<O.Ol, figure #10).
For the awake control, cortical endogenous dopamine was found to be 0.105 ug/gram of tissue (table #14).
Ketamine was the only anesthetic to lower dopamine endogenous levels in the cortex, and this was a nonsignificant 25% decrease (cf. table #14 and figure #11).

On

the other hand, halothane, nitrous oxide and the two
agents in combination increased cortical dopamine
endogenous levels, halothane alone increased dopamine
from 0.105 ug/g control to 0.184 ug/g, a 75% increase
(p<O.Ol ).

Nitrous oxide alone effected a 22% increase

in dopamine levels.

Most significant was the finding

that nitrous oxide in combination with halothane produced a dramatic 245% increase in dopamine level
(figure #11).
Awake control endogenous norepinephrine levels
in the cortex were found to be 0.160 ug/gram of tissue.
As was demonstrated in the other three brain areas,
ketamine caused a significant decrease in endogenous
norepinephrine level.

As seen in table #15 ketamine

anesthesia resulted in a significant fall to 0.075 ug/
gram of tissue, a 54% drop (figure #11 ).

Halothane

0

l.!')

N0 RE P I NE P H R I NE
C 0 RT E X
ENDOGENOUS
RATE
ug/gram
CONSTANT

TURNOVER
ng/g/hr

AWAKE CONTROL

0.160± .07

0.498

2.001

80

I

KETAMINE ANESTHESIA

0.075±,01

1.093

0.915

175

I

HALOTHANE ANESTHESIA
NITROUS OXIDE ANESTHESIA

0.255±,02
0.186±,03

1.109
1.210

0.902
0.826

177
194

HALOTHANE PLUS
NITROUS OXIDE ANESTHESIA

0.196±

2.002

0.500

320

T A B L.E

~

TURNOVER
TIME

# 15
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Tab1e #15

Effect of ketamine (40 mg/kg), ha1othane (2%),

nitrous oxide (40%), and the combination of ha1othanenitrous oxide on cortica1 dopamine.

Endogenous content

is expressed as the mean ! the standard deviation, the
rate constant is the rate of disappearance of 1 4c-dopamine
over time (i.e., the run off s1ope), turnover rate is
expressed in nanograms per gram of brain (wet weight) per
hour.

The number of anima1s in the contro1 group was 52;

in each experimenta1 group 16 anima1s were used.
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Figure #11

Effects on endogenous dopamine and norepine-

phrine in the cortex graphed as a percent of awake control.
Plots are shown for ketamine (40 mg/kg), halothane (2%),
nitrous oxide (40%), and the combination halothanenitrous oxide.

Statistical testing was accomplished by

Student's T test and significance indicated in terms of
probability (p).
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alone increased endogenous norepinephrine levels a
significant 59%.

Nitrous oxide alone did not signifi-

cantly change endogenous cortical norepinephrine levels.
The use of nitrous oxide in combination with halothane
increased the endogenous norepinephrine levels from 0.160
control, to 0.196 ug/g, a 23% increase.
Summary of cortical data:
1) Ketamine decreased dopamine turnover and
increased norepinephrine turnover.

Nore-

pinephrine endogenous levels were increased.
2) Halothane increased norepinephrine turnover
and endogenous levels and dopamine endogenous
levels.

Dopamine turnover was decreased.

3) Nitrous oxide increased only norepinephrine
endogenous levels.
4) The combination of halothane-nitrous oxide
increased dopamine and norepinephrine turnover.

Dopamine endogenous levels were also

significantly increased.

Comparison of Turnover and Endogenous
Levels Between Anesthetics:
When ketamine, halothane, nitrous oxide, and
halothane-nitrous oxide groups were compared to one
another, all dopamine endogenous and turnover level
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comparisons were significantly different with the excep-

tion of ketamine vs. halothane-nitrous oxide, turnover
only (table #16).

In the case of dopamine for these

same group comparison, all endogenous data was significantly different except for nitrous oxide vs. halothanenitrous oxide.

With respect to the norepinephrine com-

parisons, only ketamine, halothane, and nitrous oxide

,

IIIII
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vs. halothane-nitrous oxide were found significant.
Halothane Recovery:
When turnover and endogenous levels were assayed,
in animals allowed to recover for two hours post halothane anesthesia, it was found that dopamine turnover
in the mesencephalon, thalamus, hypothalamus, and cortex
returned to levels 16%, 17%,
control, respectively.

6%~

2% different from awake

None of these values demonstrated

a significant difference from control (cf. figure #12).
In the case of norepinephrine, mesencephalic
turnover returned to a level 9% below control, while
hypothalamic levels returned to a level 5% above control.
A 45% decrease in turnover was demonstrated for norepinephrine turnover in the thalamus, however, this decrease
was not significant when compared to awake control.

The

cortex showed a 101% increase in norepinephrine turnover
(p<O.Ol) post anesthesia.

This finding is similar to

that effect seen for all anesthetics studied.

1.0
LO
....-I

CORTEX
ANESTHETIC GROUP

DOPAMINE
Endogenous Turnover

NOREPINEPHRINE
Endogenous
Turnover
-

KET

vs

HAL

p <0. 01

P<0.01

P<0.01

NS

KET

vs

p <0. 01

P<O.Ol

P<O. 01

NS

KET

vs

N20
HAL + N20

p <0. 01

NS

p <0. 01

P<0.01

HAL

vs

N20

p <0. 01

p <0. 01

P<0.01

NS

HAL

vs

HAL + N20

p <0. 01

p <0. 01

P<0.01

P<0.01

N20

vs

HAL + N20

p <0. 01

p <0. 01

NS

P<0.01

I

KET

= Ketamine

HAL

= Halothane

T AB L E

.....

N20

#

= Nitrous Oxide
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Table #16

Statistical cross comparisons of endogenous

levels (Student's T test was used) and turnover rates
(covariance analysis was used) for dopamine and norepinephrine in the cortex.

Significance is indicated in

terms of probability (p); insignificant cross comparisons
are indicated by NS.

Cross comparisons for the anesthetic

groups ketamine (40mg/kg), halothane (2%), nitrous oxide
(40%), and the combination halothane (2%) plus nitrous
oxide (40%) are shown.
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Figure #12

Effects on dopamine and norepinephrine

turnover levels in the mesencephalon, thalamus,hypothalamus, and cortex two hours post halothane anesthesia graphed as a percent of awake control.
Statistical comparisons to awake control were made
by covariance analysis and reported in terms of
probability {p).

Sixteen animals were used for the

halothane recovery group.
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With regard to endogenous levels, only the
mesencephalon and cortex showed significan1 changes in
dopamine when compared to control levels.

The mesen-

cephalon showed a 51% increase (p<0.05) while the cortex
showed a 93% increase {p<O.Ol).

All brain areas studied

were found to have significant decreases in norepinephrine levels post anesthesia.

These decreases ranged

from 63% to 73% of control (cf. figure #13).
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Figure #13
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Figure #13

Effects on dopamine and norepinephrine

endogenous levels in the mesencephalon, thalamus,
hypothalamus, and cortex two hours post halothane
anesthesia graphed as a percent of awake control.
Statistical comparisons were made by Student's T
test and reported in terms of probability (p).
Sixteen animals were used for the halothane recovery
group.

CHAPTER IV
DISCUSSION
The mechanism by which anesthetic agents produce

,I

II

central nervous system anesthesia has been formally
queried since the late eighteen hundreds when Meyer
(1899) and Overton (1901) first proposed the lipid theory
of anesthesia.

Adding great impetus to this search over

the years has been the belief that knowing the central
mechanism of anesthesia would allow the tailoring of a
more perfect anesthetic agent.

Unfortunately, a careful

examination of the research findings has left more
questions unanswered than answered.
Two basic approaches to the research of anesthesia have evolved.

The first, micromolecular, is

limited in scope to the molecular interaction of
anesthetics within the cell.

Theories arising from

these works have generally tied the primary anesthetic
effect to a direct action on nerve cell components.
These theories have been discussed at length in the
Introduction of this dissertation under the Biophysical
Anesthetic Mechanism.
The second approach, macromolecular, considers
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that anesthetics affect the central synapses.

Of

importance in this concept is how anesthetics affect the
central transmitter systems.

Since comprehensive inves-

tigation into the effect of anesthetic agents on central
dopaminergic and noradrenergic nerve activity had not
been carried out, the aim of this study was to investigate anesthetic action in the central adrenergic nervous
system with particular attention to the following
questions:
1) Is the central adrenergic nervous system
affected by anesthetic agents as determined
by adrenergic amine turnover?
2) If affected, are neurons of the same type
(i.e., dopamine or norepinephrine) affected
in an identical manner in all brain regions?
3) Do clinically different anesthetics have
different effects centrally on adrenergic
neurotransmitters?
To answer these questions three clinically
different anesthetics, ketamine, halothane, and nitrous
oxide as well as the combination of halothane-nitrous
oxide were studied to determine their effect on dopamine and norepinephrine turnover in four brain areas.
The turnover data was used as an index of neuronal
activity for these two adrenergic transmitter systems
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(Costa and Neff, 1970).
With respect to the above three questions the
results of this study provide the following answers and
allow several conclusions to be drawn.
Is the central adrenergic nervous system affected
by anesthetic agents as determined by adrenergic
turnover?
Simply summarized, the turnover results from
this study show that ketamine anesthesia is associated
with significant dopamine decreases in the mesencephalon
and cortex with an increase in the hypothalamus; halothane caused similar dopamine changes in the hypothalamus
and cortex but differed in that a significant increase in
thalamic dopamine turnover was found with no change seen in
the mesencephalon.

Nitrous oxide results were markedly

different than those produced by ketamine and halothane
in that only one area was affected (i.e., an increase
in the hypothalamus).

Combination halothane plus nitrous

oxide resulted in significant increases in dopamine
turnover in the mesencephalon, hypothalamus, and
cortex or three out of four areas studied.
For norepinephrine, ketamine was associated
with an increased turnover in the cortex and a decreased
turnover in the mesencephalon.

Halothane influenced

norepinephrine turnover similarly in the cortex, did
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not produce any changes in the mesencephalon, as did ketamine, and increased norepinephrine turnover in the thalamus.
Nitrous oxide affected norepinephrine only in the cortex
(an increase).

The combination of halothane-nitrous oxide

resulted in significant increases in the thalamus and cortex.
These data indicate that anesthesia by ketamine,
halothane, nitrous oxide and the combination of halothane
and nitrous oxide is associated with altered dopamine and
norepinephrine turnover when compared to awake control.
Importantly, these results suggest why conflicting
findings on whole brain were reported.

With ketamine

anesthesia, Biggio et al. (1974) suggested an increased
dopamine turnover while Sung et al. (1973) reported a
decrease.

Both research groups used whole brain samples.

Our ketamine data clearly shows both an increase (hypothalamus) and decrease (mesencephalon and cortex) in dopamine
turnover.

With respect to halothane, our data generally

support findings of Nikki et al. (1971) and refute that
of Anden et al. (1974) and Ngai et al. (1969a), which
reported halothane to have no effect on dopamine and norepinephrine turnover in whole brain.

Our findings further

suggest that individual dopamine and norepinephrine transmitter systems operate independently of one another as both
systems demonstrated distinctly different turnover changes
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in conjunction with the same anesthetic agent.

This is

demonstrated by the finding that both ketamine and
halothane resulted in decreased cortical dopaminE
turnover, while both increased norepinephrine turnover.
Similar results were obtained by Biggio et al. (1974)
and Nikki et al. (1971 ).
Endogenous amine results obtained in this study
also support involvement of the adrenergic system with
anesthesia (significant change was observed for all
anesthetic groups except for nitrous oxide), however,
such data cannot reflect neuronal activity.

It is this

lack of correlation between endogenous levels and
neuronal activity that has led researchers to determine
turnover rather than just the endogenous content of a
transmitter to predict central neuronal activity (Costa,
1971).
the same t e (i.e.,
affected the same in
Early attempts to ascertain the involvement of
the central adrenergic system with anesthesia were
carried out on whole brain samples with little success.
Both Anden et al. (1974) and Ngai et al. (1969a) found
no effect by halothane anesthesia on norepinephrine
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and dopamine.
early failures.

Present results offer a reason for the
With all anesthetics studied:

ketamine,

halothane, nitrous oxide, and halothane-nitrous oxide,
the change in NE and DA turnover in individual brain
regions was non-uniform.

Increased turnover in one brain

area with decreased turnover in another area, approximately in proportion, as was the case with halothane
dopamine turnover, would mask by cancellation anesthetic
effects on turnover when whole brain samples are used
as in the earlier studies.
Importantly, this study has provided evidence
of non-uniform regional changes in dopamine and norepinephrine neuronal activity associated with anesthesia.
The concept that anesthetics have regionally different
central actions was previously proposed by Roizen (1976)
on the basis of endogenous catecholamine data and local
changes
1978).

in

glucose metabolism

(Shapiro

et

al.,

Likewise, Ngai et al. (1978) proposed regional

effects for halothane and cyclopropane with respect to
acetylcholine turnover.

Clearly, the evidence supports

regional effects of anesthetics on neural activity,
however the effect varies from region to region.

The

meaning of these regional differences relative to anesthesia remains at present elusive.
To postulate that the demonstrated regional

r
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turnover changes for dopamine and norepinephrine are
related, at least temporally to anesthesia, one should
expect these turnover changes to revert to awake control
levels post anesthesia.

A test of this hypothesis
I

~

demonstrated two hours post halothane anesthesia that
turnover changes seen during anesthesia do in fact revert
to values not significantly different from the awake
control.

Only cortical norepinephrine turnover did not

return to the pre-anesthetic level.

Interestingly,

the only effect common to all agents during anesthesia
was this increase in cortical norepinephrine turnover.
The relationship of this effect to the increased
norepinephrine turnover post anesthesia is unknown.
Do clinically different anesthetics have different
effects centrally on adrenergic neurotransmitters?
The anesthetics used were chosen for their
differences in clinical effect.

There are now many

classes df anesthetic agents (e.g., dissociative, inhalation, narcotic, barbiturate) each with its own clinically unique type of anesthesia.

Some agents have good

hypnotic action, while having little to no analgesic
activity (e.g., barbiturates), while others produce good
analgesia at clinical doses (e.g., ,N 20). It is unknown
whether or not all anesthetics have common effects

I

li

i

centrally, although common sense might dictate that

i!'
1
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clinically different anesthetics should result in different central effects as well.

To test this hypothesis,

individual ketamine, halothane, nitrous oxide, and
halothane-nitrous oxide turnover and endogenous amine
data from the same brain region were cross-correlated.
By design, a significant difference in turnover activity
between the two anesthetic agents being compared indicated a different effect of each agent on that amine
system.

And conversely, a lack of significance between

the effects of different anesthetics was interpreted to
indicate a similarity in effect on that brain region.
This type of a comparison is problematic and generally
limited in scope for the following reasons.

It is

difficult to provide evidence of equal anesthetic depth
between intravenous and inhalation anesthesia.

Nitrous

oxide at the concentration used is only analgesic, not
anesthetic.

It is also well documented that the addition

of nitrous oxide to halothane increases halothane's
potency.

Therefore, in this study where the same con-

centration of halothane is used with and without nitrous
oxide the levels of anesthesia of these two groups must
be different.
Even though there are differences in anesthetic
level these comparisons allow one to determine qualitative differences between these clinically different
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anesthetics.

This is an important step in determining

similarities of effect on central neurotransmitter
systems by anesthetic agents.
Ketamine vs. Halothane:
Ketamine anesthesia has been termed

11

dissociative 11

and is characterized by possible increases in EEG activity, profound analgesia, normal muscle tone, and catatonia.
Halothane is a potent anesthetic marked by poor analgesia, depressed EEG activity, minimal depression of
neuromuscular junctions, and causes profound narcosis.
These two agents present themselves as clinically
different anesthetics.
When ketamine turnover was compared with that of
halothane, dopamine turnover levels were significantly
different in all four brain regions.

Norepinephrine

turnover comparisons were significantly different in two
areas, the mesencephalon and thalamus, and not different
(or similar) in the other two areas, hypothalamus and
cortex.

The conclusion derived was that ketamine and

halothane have dissimilar patterns of effect on regional
amine metabolism.

This conclusion is supported by

multi unit electrophysiological findings which also show
regional differences for these two anesthetics (Domino,
1968; Massopust et al., 1972).

r
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Ketamine vs. Nitrous Oxide; Ketamine vs. Nitrous
Oxide-Halothane:
Nitrous oxide, when used in clinical concentrations, is a potent analgesic agent with few other
clinically significant effects.

Nitrous oxide is

therefore similar to ketamine as an analgesic.
Comparison of dopamine and norepinephrine
turnover data for ketamine and nitrous oxide demonstrated some similarities for these two agents.

Thalamic

and hypothalamic dopamine changes were similar, while
norepinephrine turnover was significantly different in
three out of the four areas studied, the thalamus,
hypothalamus, and cortex.

Further, when ketamine data

is compared to the halothane-nitrous oxide combination
there were fewer areas of significant difference compared
to halothane alone and more areas of difference when
compared to nitrous oxide alone, which is qualitatively
what one might expect.

It should be noted that this

comparison is based on the overall number of significant
findings.
Halothane vs. Nitrous Oxide:
When halothane and nitrous oxide were compared
one might anticipate different effects in central
adrenergic activity since these are two quite different
clinical agents.

When turnover data was compared some

~

~
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areas showed similarity of effect and some statistically different effects.

The thalamus, hypothalamus,

and cortex showed significantly different dopamine
changes, while in the case of norepinephrine, turnover
comparisons showed different effects in the mesencephalon
and thalamus.

It can be concluded that halothane and

nitrous oxide each alter regional adrenergic neuronal
activity in a different fashion.
Halothane vs. Halothane-Nitrous Oxide;
Nitrous Oxide vs. Halothane-Nitrous Oxide:
Comparison of the halothane-nitrous oxide
combination to halothane alone and nitrous oxide alone
provided an interesting finding.

The overall effect on

turnover due to halothane-nitrous oxide combination was
greater than either agent alone or the sum of the individual turnover effects.

In the mesencephalon and

thalamus, the magnitude of change indicated a supraadditive effect, while in cortex a complete reversal in
the direction of change occurred.

These findings are

novel insofar as central adrenergic neural activity is
involved, although in the periphery several authors
have suggested that the combination of halothane plus
nitrous oxide results in measured effects attributable
to neither agent alone.

Hornbein et al. (1969) and

Bahlman et al. (1971) measured cardiovascular and
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respiratory parameters, while Smith et al. (1970)
recorded sympathetic out flow.

Both groups found a

disproportionate increase in response when nitrous
oxide was added to halothane anesthesia.

Fukunaga and

Epstein (1973) found a large increase in sympathetic
out flow when nitrous oxide was added to halothane,
however, if the same animal had a mid-collicular lesion,
addition of nitrous oxide was then found to cause a
decrease in sympathetic activity.

These authors postu-

lated a supra-collicular site as responsible for the
combined effects.
Although evidence of central and peripheral
supraadditive anesthetic actions has been demonstrated,
the mechanism and/or significance of these actions
remain unknown.
It can be concluded from this study that the
clinically different anesthetics ketamine, halothane,
nitrous oxide, and the combination halothane-nitrous
oxide do produce individual (supraadditive) effects on
regional central catecholamine turnover.

Anesthesia in Relation to Transmitter
~stems - a Perspective:
When one considers change in adrenergic turnover
relative to anesthesia, it is important to consider the
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direction of the observed change.

Conceptually, it would

seem easier to relate a decrease rather than increase in
neuronal activity to a state of anesthesia.

This stems

from the long standing, and generally unproven, hypothesis that the CNS is deactivated during anesthesia.

This

concept began to change when Winters et al. (1967)
reclassified anesthetic agents with respect to EEG
activity during surgical anesthesia.

He found that not

all agents acted in the classical sense to cause EEG
depression.

Ether, barbiturate, and halothane did act

in this fashion, while such agents as nitrous oxide,
gama hydroxybutyrate, phencyclidine, ketamine and
enflurane all could increase brain EEG activity at
clinical

dose~.

It has been considerably more difficult to
obtain a good neurochemical correlate similar to that of
EEG activity to relate to anesthesia.

Recent evidence

has related cholinergic neuronal activity to both EEG
activity and anesthesia (Ngai et al., 1978).

Anesthet-

ics shown to decrease EEG activity have also been shown
to decrease acetylcholine turnover, while other anesthetics known to increase EEG activity have been shown
in some cases to increase acetylcholine turnover (Ngai
et al ., 1978).

Moreover, clinical and experimental

evidence utilizing various cholinergic agonists and
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antagonists have demonstrated that cholinergic manipulation will affect the anesthetic process (Winter, 1976;
Horrigan, 1978).

Importantly, physostigmine has been

shown in humans to reduce the recovery time post anesthesia (Smith et al., 1976).
The central cholinergic system probably does not
act as an independent neurochemical system (Sethy et
al ., 1976).

The complex neuronal circuitry containing

known and unknown transmitters that appear to work in
concert have yet to be sufficiently unraveled.

Results

from this study suggest the premise that reported
increases and decreases in cholinergic activity with
anesthesia might be the result of induced changes from
stimulatory or inhibitory neurotransmitter systems.
Serotonin turnover has been generally shown to
decrease with anesthesia (Sung et al., 1973; Bourgoin
et al ., 1975) and gamma-amino butyric acid (GABA), a
known central inhibitory transmitter, was proposed by
Cheng and Brunner (1975) to cause post synaptic inhibition and anesthesia through increased GABA concentration in the cortex.

Other work related to GABA has

been carried out using gamma-butyrolactone, a precursor
to GABA, and gamma-hydroxybutyrate (GHB), a metabolite
of GABA and an anesthetic agent itself.

Gessa et al.

(1966) demonstrated that GHB-induced anesthesia was
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associated with significant increases in brain dopamine.
A concomitant decrease in acetylcholine turnover with
GHB anesthesia was suggested by the data of Sethy et al.
(1976).

Further gamma-butyrolactone was demonstrated to

increase central dopamine content presumably by increasing tyrosine hydroxylase activity (Murrin and Roth,
1976).
Johnston et al. (1975) and Batista et al. (1973)
have postulated dopamine to be an inhibitory transmitter
in relation to anesthesia.

In general, results from this

study show that anesthetics outlined by Winters et al.
(1967) to decrease EEG activity (halothane in this study)
caused increased dopamine turnover in almost all brain
areas studied.

Conversely a decrease in dopamine turn-

over was seen with anesthetics which caused increased
EEG activity (ketamine and nitrous oxide in this study).
This inverse relationship between EEG activity and
acetylcholine turnover (Ngai et al ., 1978) and dopamine
turnover (this study) could relate to an inhibitory
effect of dopamine on the central cholinergic neurotransmitter system with resultant anesthesia.

Such

an acetylcholine inhibition by dopamine is known to
exist in the nigrostriatal system (Cooper et al ., 1974).
In the same context, nitrous oxide when added to halothane anesthesia is known to increase halothane

1

S

potency (as previously discussed).
theory of anesthesia would
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This dopamine based

predict a potentiation of

the halothane induced increase in dopamine turnover when
nitrous oxide is added to halothane.

This was demon-

strated in this study.
Further support of dopamine involvement during
anesthesia comes from studies by Fyro et al. (1975), who
have shown in humans that halothane-nitrous oxide anesthesia increases homovanillic acid (HVA) output into the
cerebral spinal fluid strongly suggesting an increase
in dopamine turnover and therefore dopaminergic nerve
activity.
Additional supportive evidence comes from
studies using anti-dopaminergic compounds such as
pimozide, which was shown to antagonize certain types
of anesthesia (Hatch, 1974) while drugs known to elevate dopamine concentration such as L-dopa have been
shown to increase anesthetic potency (Johnston et al.,
1975).
Thus accumulating evidence from both animal and
human studies support the concept of increased neuronal
activity in a proposed central dopamine inhibitory
system during anesthesia.

The validity of this hypo-

thesis must await future experimental results.
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SUMMARY

To summarize the findings of this study, it was
demonstrated that the anesthetic agents ketamine, halothane,
nitrous oxide and the combination of halothane - nitrous
oxide significantly alters dopamine and norepinephrine
turnover in select brain regions.
results

In brief, ketamine

in a significant decrease in both mesencephalic

and cortical turnover and an increase in hypothalamic
dopamine turnover.
rine turnover.

Ketamine decreased cortical norepineph-

HaJothane results were different from those

found with ketamine.

Increased thalamic and hypothalamic

dopamine was found with a concomitant decrease in cortical
dopamine turnover.

Halothane increased both thalamic and

cortical norepinephrine turnover.

Two hours post halothane

anesthesia, turnover rates in all brain areas affected were
found to have returned to control except for cortical norepinephrine.

Nitrous oxide had only two effects on catechol-

amine turnover.

An increase in hypothalamic dopamine and an

increase in cortical norepinephrine were found.

Of interest

were the large changes in turnover found when halothane nitrous oxide combination was used.

This combination re-

sulted in a dramatic increase in dopamine turnover in the
mesencephalon, hypothalmus and cortex.

Large increases in

thalamic and cortical norepinephrine were also found.
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Several conclusions were drawn from this data
(1) It was determined that adrenergic turnover is
effected by the anesthetics ketamine, halothane, and
nitrous oxide at clinical doses.

This suggests a role

for these neurotransmitter systems in anesthesia.
(2) Dopamine and norepinephrine metabolism were found
to be independently altered by these anesthetic agents,
indicating a possible distinct role for each neurotransmitter.

(3) Effects of these anesthetics were found not

to be uniform throughout the brain.

This could account

for many of the discrepancies in previous turnover studies
using whole brain.

(4) The reversal of the halothane

effects two hours post anesthesia denotes a strong temporal
relationship between the state of anesthesia and· the
alteration of adrenergic turnover.

(5)

Anesthetic agents

which are clinically different were shown to also differ
in their effect on central adrenergic turnover.

(6) The

data from this study coupled to evidence obtained from
animal and human studies supports the concept of increased
neuronal activity during anesthesia in proposed inhibitory
transmitter systems.
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APPENDIX

A

B R A I N WE I G H T S
(in grams)
MES.

THAL.

HYPO.

CORT.

Awake Control

0.75±.02* 0.55±.02

0.35±.01

1.98±.05

Ketamine

0.74±.03

0.56±.02

0.33±.02

1.99±.03

Halothane

0.72±.02

0.58±.02

0.34±.01

1.95±.06

Nitrous Oxide

0.75±.02

0.58±.02

0.36±.02

2.08±.05

Halothane +
Nitrous Oxide

0.70±.03

0.54±.04

0.32±.03

2.05±.04

Halothane
Recovery

0.71±.04

0.60±.03

0.33±.01

2.14±.06

* Mean

MES. =
THAL.=
HYPO.=
CORT.=

± SE
Mesencephalon
Thalamus
Hypothalamus
Cortex
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M0 N I T 0 R I N G

B

VAL UE S

Parameter

Range of Values

1) Pao 2
2) PaC0 2

350 - 450 torr

3) pH

34 - 39

torr

7.34- 7.40

4) Temperature

39 - 39.5°C

5) X Arterial Blood Pressure

92

-

110 torr

12.3

±

0.8 mg%

6) Halothane Blood Levels

Note:

All values shown are within normal limits for rabbit.
The Pao 2 r~nge for ketamine was 86 - 100 torr
due to room air spontaneous ventilation.
Halothane blood levels are consistent with
published values.

202

APPROVAL SHEET

The dissertation submitted by Byron C. Bloor has been read
and approved by the following committee:
Dr. Silas N. Glisson, Director
Associate Professor, Department
of Anesthesiology and Pharmacology
Loyola University
Dr. Alexander G. Karczmar,
Professor and Chairman, Department
of Pharmacology and Experimental
Therapeutics, Loyola University
Dr. Adel A. El-Etr,
Professor and Chairman, Department
of Anesthesiology, Loyola University
Dr. Alexander Friedman,
Associate Professor, Department of
Pharmacology and Experimental
Therapeutics, Loyola University
Dr. Michael Collins,
Associate Professor, Department
of Biochemistry, Loyola University
The final copies have been examined by the director of the dissertation
and the signature which appears below verifies the fact that any
necessary changes have been incorporated and that the dissertation is
now given final approval by the Committee with reference to content and
form.
The dissertation is therefore accepted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy.

f-l-79

//

~

A/J

~

1'\'D'="'atre~--'-----J;~--4--/~~------,~r'~

